

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

20 Abstract

21 **Background:** Cotrimoxazole and isoniazid preventive therapy (CPT, IPT) have been shown
22 to be efficacious therapies for the prevention of opportunistic infections and tuberculosis (TB)
23 among people living with human immunodeficiency virus (HIV). Despite governments' efforts
24 to translate World Health Organization recommendations into practice, implementation
25 remains challenging. This review aimed to explore and compare CPT and IPT with respect
26 to similarities and differences of barriers identified across high TB/HIV burden countries. A
27 secondary objective was to identify facilitators for implementing both preventive therapies.

28 **Methods:** We searched MEDLINE, Web of Science and SCOPUS databases for peer-
29 reviewed literature published before September 2020. We extracted and synthesized our
30 findings using Maxqda software. We applied framework synthesis in conjunction with
31 metasummary to compare both therapies with respect to similarities and differences of
32 barriers identified across seven health system components (in line with the modified WHO's
33 Framework for action). Protocol registration: PROSPERO (CRD42019137778).

34 **Findings:** We identified four hundred and eighty-two papers, of which we included forty for
35 review. Although most barrier themes were identical for both preventive therapies, we
36 identified seven intervention-specific themes. Like for CPT, barriers identified for IPT were
37 most frequently classified as 'service delivery-related barriers' and 'patient & community-
38 related barriers'. 'Health provider-related barriers' played an additional important role for
39 implementing of IPT. Most facilitators identified referred to health system strengthening
40 activities.

41 **Conclusions:** For researchers with limited working experience in high TB/HIV burden
42 countries, this review can provide valuable insights about barriers that may arise at different
43 levels of the health system. For policymakers in high TB/HIV burden countries, this review
44 offers strategies for improving the delivery of IPT (or any newer therapy regimen) for the

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

45 prevention of TB. Based on our findings, we suggest initial and continuous stakeholder
46 involvement, a focus on the efficient use and reinforcement of existing resources for health.

47 **Key words:** Implementation, HIV, Tuberculosis, Cotrimoxazole, Isoniazid, Systematic
48 review, Metasummary, Health systems strengthening, Global Health

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

49 Introduction

50 Background

51 In 2019, 38 million people worldwide were living with the human immunodeficiency
52 virus (HIV) [1]. An estimated quarter of the world's population was latently infected with
53 *Mycobacterium tuberculosis*; 10 million developed active tuberculosis (TB) [2, 3]. The fact
54 that HIV-positive individuals have 20 times higher risk of developing active TB disease
55 compared to HIV-negative individuals has been described as a lethal combination [4], which
56 has transformed many low- and middle-income countries (LMIC) into countries with a high
57 dual burden of TB and HIV [2]. The latest UNAIDS report continues to present TB as the
58 leading cause of death among people living with HIV (PLHIV), accounting for around one in
59 three AIDS-related deaths worldwide [1]. This review focuses on the implementation of two
60 of the most important preventive therapies for PLHIV in countries with a high burden of
61 TB/HIV: cotrimoxazole (CTZ) and isoniazid (INH).

62 Cotrimoxazole (CTZ) is a fixed-dose combination of trimethoprim/ sulfamethoxazole
63 that combines broad antimicrobial activity with immunomodulatory properties. Besides
64 preventing some AIDS-associated opportunistic diseases (*Pneumocystis jirovecci*
65 pneumonia (PCP), toxoplasmosis), CTZ has shown to be successful in reducing malaria,
66 severe bacterial infections, and mortality among PLHIV. As a result, World Health
67 Organization (WHO) recommends cotrimoxazole preventive therapy (CPT) lifelong for
68 PLHIV in resource-limited settings where malaria and, or severe bacterial infections are
69 highly prevalent, irrespectively of their CD4 count. In settings were neither malaria nor
70 severe bacterial infections are highly prevalent, CPT is recommended for PLHIV with severe
71 or advanced HIV disease (WHO clinical stage 3 or 4, or CD4 count below 350 cells/mm³),
72 and may be discontinued for those with evidence of immune recovery or viral suppression on
73 antiretroviral treatment (ART). Adults, including pregnant women, children and adolescents

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

74 with HIV, and HIV-exposed but uninfected infants, as well as PLHIV with active TB, are
75 eligible for CPT, including those concurrently receiving ART [5].

76 Isoniazid (isonicotinylhydrazide or INH) is the most common type of TB preventive
77 therapy. With its anti-mycobacterial activity, isoniazid monotherapy is prescribed to treat latent
78 TB infection and prevent the progression from latent to active TB. WHO recommends at least
79 six months of isoniazid preventive therapy (IPT) to people at risk of TB living in resource-
80 constrained and high TB and HIV prevalence settings. PLHIV comprise a major risk group for
81 TB, among which IPT has shown to reduce TB disease and mortality irrespective of receiving
82 ART. Therefore, PLHIV unlikely to have active TB, are eligible for IPT. This includes HIV-
83 positive positive adults including pregnant women, adolescents, infants aged under 12 months
84 who are in contact with a TB case, and children older than 12 months who have no contact
85 with a TB case. HIV-negative children aged under 5 years who are household contacts of
86 people with bacteriologically confirmed pulmonary TB comprise another target group for IPT.
87 Independent of the target group, only people with unknown or a positive tuberculin skin test
88 (TST) unlikely to have active TB are eligible for IPT. In the absence of TST, patients should be
89 screened for TB according to a clinical algorithm. Those who do not report any of the
90 symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB
91 and should be offered preventive therapy, irrespective of the degree of immunosuppression
92 and including those who have previously been treated for TB [4].

93 **Rationale**

94 Data from clinical trials and observational studies demonstrated that both preventive
95 therapies are well-tolerated, highly efficacious, and cost-effective among PLHIV [6-10],
96 resulting in WHO recommendations that were first adopted almost two decades ago [11, 12].
97 With increasing evidence supporting the benefits of the preventive therapies for PLHIV,
98 WHO recommendations have been even expanded with regard to therapy duration and
99 target populations indicated for CPT and IPT in today's recommendations [5, 13]. Although

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

100 efforts have been made by governments of high TB/HIV burden countries and their partners
101 to translate these recommendations into national policy and practice, implementation of both
102 preventive therapies has been challenging and coverage has been low [2, 14, 15].

103 **Objectives**

104 The primary objectives of this review were to explore barriers to both preventive
105 therapies reported across high TB/HIV burden countries (as per WHO [2]) and to generate
106 explanatory knowledge of why their implementation has been so challenging. Additionally,
107 this review aimed to compare both preventive therapies with respect to similarities and
108 differences of barriers. A secondary objective was to identify strategies (facilitators) to
109 improve the implementation of both preventive therapies. To identify relevant research, the
110 broad question: “Which are the barriers to and facilitators for the implementation of
111 preventive therapies (CPT, IPT) in countries with a high burden of HIV and TB?” was
112 designed using FINER criteria [16] and the PICo framework: Population, Interest, Context
113 (modified PICO) [17] (S1 Additional file). Barriers were defined as factors that limit, challenge
114 or inhibit implementation, access, provision, delivery, or adherence to CPT or IPT.
115 Facilitators were defined as factors that facilitate, support, encourage, or enable the
116 implementation, access, provision, delivery, or adherence to CPT or IPT. In the published
117 literature, the treatment of interest may be referred to as ‘preventive therapy’, ‘preventive
118 treatment’, ‘prophylaxis’ or ‘prophylactic treatment’.

119 **Methods**

120 **Protocol and registration**

121 Following the Joanna Briggs Institute (JBI) methodology for mixed methods
122 systematic review, we developed a protocol prior to undertaking the review [17, 18], which
123 we registered and published in PROSPERO (CRD42019137778) (S2 Additional file). As
124 outlined in section 8.5.1 of the JBI Reviewer’s Manual, we applied a convergent integrated

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

125 approach to synthesis and integration [18]. We followed PRISMA guidance and reported our
126 findings, according to the PRISMA checklist (S3 Additional file) [19].

127 **Eligibility criteria**

128 Only peer-reviewed scientific papers meeting all of the following eligibility criteria
129 were included: (1) papers reporting barriers and, or facilitators for either or both preventive
130 therapies (CPT, IPT), sometimes in the literature also referred to as ‘preventive treatment’,
131 ‘prophylaxis’, or ‘prophylactic treatment’. (2) Only studies conducted in high TB/HIV burden
132 countries defined by WHO in the period 2016 to 2020 [2]; (3) published in English language;
133 (4) until the 4th of September 2020 were eligible for this review. (5) Studied populations
134 eligible were: (a) HIV patients or PLHIV. Although HIV-negative population groups may be
135 eligible for IPT (e.g. household contacts of TB cases), HIV-negative population groups were
136 not within the scope of this review. However, for CPT, HIV-exposed babies (HIV suspects)
137 were eligible study populations, as well as patients co-infected with TB and HIV. Other
138 studied populations eligible were (b) healthcare providers, also referred to as health
139 professionals; (c) caregivers (i.e. parents or guardians of child patients involved in the
140 preventive therapy collection or drug administration process); (d) any other stakeholder
141 identified as influential in the overall implementation process of either IPT or CPT, and (e)
142 countries defined by WHO as high TB/HIV burden countries [2]. Since this systematic review
143 aims to analyse studies reporting primary data, we excluded editorial comments and
144 systematic reviews. However, we screened reference lists of systematic reviews for original
145 research eligible for this review. We included studies conducted in multi-sites or multiple
146 countries only if barriers/ facilitators were separately analysed and reported per site or
147 country. Because of the limited number of published qualitative studies on this topic, we
148 included primary studies of any design (i.e. qualitative, quantitative, multimethod and mixed
149 methods studies).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

150 **Information sources and search**

151 In February 2018, we systematically searched the electronic databases MEDLINE®,
152 Web of Science® and Scopus® for original articles using the search terms presented in (S4
153 Additional file). We repeated the search in September 2020 to identify additional literature
154 published after February 2018 and updated our review [20]. The full electronic search
155 strategy is available for each database search (S4 Additional file). We searched references
156 of systematic reviews only if the systematic review was relevant to the study question.

157 **Study selection**

158 Following the search, PM collated and uploaded all identified citations into Endnote X9
159 reference management software, and removed all duplicates. We both independently
160 screened and assessed all titles and abstracts against the predefined eligibility criteria for
161 this review. Non-relevant studies and studies reporting from countries other than the thirty
162 high TB/HIV burden countries were excluded during this initial title and abstract screening
163 process. When the decision on exclusion was not clear, we included the study for full-text
164 screening. PM retrieved the full-text of all potentially relevant studies. Eventually, we both
165 independently assessed the full-text of the remaining studies against the eligibility criteria.
166 Studies that did not meet all eligibility criteria were excluded, and reasons for exclusion were
167 recorded. Studies that met all eligibility criteria were included. We compared our decision
168 (i.e. inclusion/ exclusion and reason for exclusion) for each of the selected studies,
169 discussed their full-text and resolved any disagreement concerning our decision through
170 discussion.

171 **Data collection process and data items**

172 We developed a data extraction table which we initially tested on three studies to
173 ensure that all relevant data items could be extracted. PM extracted the following data items
174 from each included study: first author, year of publication, geographic origin (one or multiple

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

175 countries defined as high burden country for TB/ HIV), context (e.g. urban, rural), study type,
176 study subject(s) of interest, sample size of study subjects for each data collection approach,
177 study aim(s), data collection approach (e.g. interviews, record review), and findings related
178 to the review question (i.e. barrier(s) and, or facilitator(s) for CPT, IPT, or both). LVL checked
179 the extracted data items for accuracy and added or modified data items were necessary. We
180 compared the data we individually extracted and resolved any disagreement through
181 discussion.

182 **Data transformation**

183 As outlined in Section 8.5.1 of the JBI Reviewer's Manual, we extracted findings (barriers
184 and facilitators) from quantitative, qualitative and mixed methods studies. Qualitative findings
185 including the qualitative component of mixed methods studies were extracted as presented
186 in the original research paper (e.g. themes, corresponding illustrations, paragraphs of textual
187 description). We transformed quantitative findings, including the quantitative component of
188 mixed methods studies, into textual description disregarding the effect size [18]. For
189 example: "A quantitative study reported a twenty per cent decrease in cotrimoxazole stock-
190 outs ($p < 0.05$) among health facilities that had employed trained pharmacy personnel,
191 compared to health facilities without any trained pharmacy personnel." From this fictitious
192 example, the following information would have been extracted: (1) Finding: Facilitator for
193 CPT; (2) Description: employment of trained pharmacy personnel has shown to decrease
194 stock-outs. Finally, we merged qualitative findings and transformed study findings together
195 into one data set.

196 **Risk of bias in individual studies**

197 Due to the methodological diversity of the studies included in MMSR's, the selection
198 of an appropriate tool that allows assessing the methodological quality of included studies is
199 particularly challenging for this type of review. For the critical appraisal of methodological

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

200 quality (internal validity) of the included studies, we selected the “Mixed Methods Appraisal
201 tool” (MMAT), version 2018 [21]. The MMAT is a critical appraisal tool designed for the
202 appraisal process of mixed methods reviews because it specifically addresses items related
203 to the various study designs being evaluated in a single tool [21]. Methodological quality
204 criteria to be rated in the MMAT are specific for (a) qualitative research, (b) randomised
205 controlled trials, (c) non-randomised studies, (d) quantitative descriptive studies, and (e)
206 mixed methods studies (S5 Additional file). As reported by the Cochrane Qualitative and
207 Implementation Methods Group, this tool has been used widely in systematic reviews and
208 has the advantage of being able to assess interdependent qualitative and quantitative
209 elements of mixed-methods research [22]. We independently assessed methodological
210 quality based on the details published in the studies included in our review using the MMAT
211 [21]. We resolved any disagreement in rating through discussion. To preserve the
212 transparency of the risk of bias assessment, we documented all individual ratings for each
213 study included in this review. For studies that failed to meet more than one quality criteria,
214 we discussed whether to exclude the study. However, we also considered that our study's
215 focus was on qualitative findings and on the generation of explanatory knowledge of why the
216 implementation of both preventive therapies has been so challenging. Due to the risk of
217 excluding insights relevant for a good understanding of the phenomenon under study, which
218 may only become apparent at the point of synthesis, bias was toward inclusion [23, 24].

219 **Qualitative synthesis**

220 We applied framework synthesis, a highly transparent and deductive approach
221 recommended for the synthesis of evidence on complex interventions [25]. This approach
222 allows combining elements of critical realistic and subjective idealistic epistemology. We
223 analysed our data set using MAXQDA Analytics Pro software (Release 18.1.1.), iteratively
224 coding and sub-coding the extracted results. Both researchers individually defined, cross-

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

225 checked, discussed and refined the code system. We resolved disagreement through
226 discussion.

227 Inspired by Getahun et al. (2010) [26], we applied a priori defined modified version of
228 the WHO's Framework for action [27] to analyse and present barriers to preventive
229 therapies. First, we assigned each extracted result (i.e. barrier) to one of the seven health
230 system components based on the level at which they hindered implementation. Health
231 system components include 'Patient & community', 'Health providers', 'Clinical information',
232 'Leadership & governance', 'Pharmaceutical management', 'Service delivery' and
233 'Financing'. We slightly modified three of the original component names and added the
234 component "Patient & community" as the seventh component to the existing framework.
235 Second, we thematically analysed each barrier considering its contextual description. Third,
236 to summarise the comprehensive barrier descriptions, we applied metasummary.
237 Metasummary is a quantitatively oriented aggregation of qualitative findings first proposed by
238 Sandalowsky, Barroso and Voils (2007) [24, 28]. Mapping of key barriers across the seven
239 health system components facilitated comparison of similarities and differences of barriers
240 between both preventive therapies [25].

241 For facilitators, we applied 'the preventive therapy cascade' as framework for
242 evidence synthesis. After familiarising ourselves with the extracted data set, reading and re-
243 reading the identified facilitators and exploring underlying patterns, we found that facilitators
244 generally aimed to enhance specific activities (e.g. providers' prescribing practices, patients'
245 adherence) along a series of steps involved in the implementation of preventive therapies.
246 Eventually, the preventive therapy cascade emerged as most relevant framework for the
247 synthesis and presentation of our data, featuring each step along the preventive therapy
248 cascade with all its bottlenecks. We assigned each extracted result to one or multiple steps
249 along the cascade, followed by thematic analysis, inductively grouping facilitators into
250 overarching themes [25].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

251 **Risk of bias across studies**

252 Published studies are more likely to report statistically significant results compared to
253 unpublished studies. Hence, publication bias compromises reviewers' ability to assemble a
254 complete body of evidence that is not biased towards "positive findings". Although
255 publication bias is primarily a concern for systematic reviews evaluating an intervention's
256 effect, it is debatable whether the consequences of such bias is as potentially serious in
257 qualitative evidence synthesis [29]. Dissemination bias (which encompasses publication
258 bias) is gaining increasing attention in qualitative evidence synthesis. More research is
259 required on how to assess dissemination bias in the context of qualitative evidence
260 syntheses [30].

261 **Additional analysis**

262 Due to the complexities associated with findings derived from both streams of
263 evidence and the impact of data transformation and integration on the grading process, an
264 assessment of the certainty of the evidence is currently not recommended for MMSR's [18].
265 However, we analysed heterogeneity of the countries and the study subjects represented in
266 this review and discussed potential limitations resulting from a heterogeneous representation
267 of these variables.

268 **Results**

269 **Study selection**

270 The PRISMA Flow Diagram presents the number of papers included throughout the
271 selection process, alongside with the reasons for exclusion (Fig 1).

272 **Fig 1. PRISMA Flow Diagram.**

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

273 **Description of studies included in the systematic review**

274 Forty studies were included for review, fourteen related to CPT [14, 15, 31-42] ;
275 twenty-eight related to IPT [14, 38, 43-68], including two studies that reported findings on
276 both preventive therapies [14, 38]. While facilitators were reported in all studies, barriers
277 were not presented in three studies [32, 40, 41], all related to CPT. Comparing the year of
278 the first publication included for both preventive therapies, we found that the first study
279 included on IPT has been published fourteen years before the first study on CPT (1995,
280 2009) [38, 44]. All studies related to CPT were carried out in WHO African Region [14, 15,
281 31-42], while studies related to IPT also included WHO South East Asia Region [47, 61, 62],
282 WHO Western Pacific Region [47] and WHO Region of the Americas [46, 47] (Fig 2).

283 **Fig 2. Regional representation of countries included in this review.** (A) High TB/HIV burden
284 countries represented in studies reporting barriers or facilitators for cotrimoxazole preventive therapy (n= 7):
285 Ghana, Malawi, South Africa, Tanzania, Uganda, Zimbabwe and Lesotho (published between 2009 and 2018).
286 (B) High TB/HIV burden countries represented in studies on IPT (n= 22): Angola, Botswana, Brazil, China, DRC,
287 Ethiopia, India, Indonesia, Kenya, Lesotho, Liberia, Malawi, Mozambique, Myanmar, Nigeria, South Africa,
288 Swaziland, Tanzania, Thailand, Uganda, Zambia and Zimbabwe (published between 1995 and 2020). Source:
289 Own visualization of review data: <https://www.amcharts.com/>.

290 Among the thirty countries defined by WHO as countries with a high burden of TB
291 and HIV [2], we identified research from twenty-three countries (77%) reporting barriers or
292 facilitators to either or both preventive therapies. Countries were disproportionately
293 represented. The majority of studies were conducted in South Africa (n = 11) [37, 42, 47, 50-
294 52, 54, 63-65, 67], Uganda (n = 9) [31-33, 38-40, 44, 56, 66], Tanzania (n = 5) [15, 35, 36,
295 47, 60], Kenya (n = 4) [45, 47, 49, 68], Zimbabwe (n = 3) [33, 34, 47], Ethiopia (n = 3) [47,
296 53, 58], and Nigeria (n = 3) [43, 47, 57]. Another fifteen countries were represented in only
297 one or two studies. All studies, except three [33, 47, 49] based their findings on data
298 collected in one single country. Half of the studies missed to mention the context where the
299 study was carried out. Among the twenty studies that reported the context, ten were

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

300 conducted in urban areas [33, 35, 36, 41, 44, 45, 49, 58, 67, 68], eleven in rural areas [33,
301 38, 39, 42, 45, 49, 50, 55, 62, 63, 66] and six in intermediary areas [33, 38, 42, 44, 51, 65]
302 (i.e. peri-urban, sub-urban, and semi-urban context). Some studies were conducted in
303 multiple contexts.

304 Patients (n = 24) [31, 32, 35, 36, 38, 43, 44, 46, 48-52, 54, 55, 58-66], health providers (n =
305 14) [14, 15, 36, 38, 39, 45, 46, 51, 53, 54, 62, 63, 67, 68], and health facilities (n = 14) [15,
306 33, 36, 37, 39-42, 44, 45, 49, 56, 57, 67] were the study subjects of interest most frequently
307 represented in this review, with at least one of the three study groups included in thirty-eight
308 studies (95%). Few studies included other study subjects, explicitly caregivers [15, 34],
309 community members [38], other stakeholders [14, 45, 46, 56], districts [38], and countries
310 [47]. Table 1 shows the main characteristics of the studies included in this review.
311 Additionally, we provided a more detailed presentation of study characteristics separately for
312 studies on CPT and IPT (S6 Additional file).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

313 **Table 1. Main characteristics of the studies included in this review.**

First author [citation]	Year of publication	Country	Study type	Study subjects	Data collection approach	Treatment of interest
Adepoju [43]	2020	Nigeria	Retrospective cohort study	Patients	Record review	IPT
Aisu [44]	1995	Uganda	Operational Assessment	Patients, Facilities	Clinic attendance monitoring, Adherence (Pill count), Interviews, Review of key documents	IPT
Ansa [41]	2014	Ghana	Comparative research	Facilities	Record review	CPT
Catalani [45]	2014	Kenya	Mixed methods assessment	Providers, Other stakeholders, Facilities	Key informant interviews, Qualitative field notes of site observations, Interviewer-administered survey, In-depth interviews	IPT
Chan [33]	2014	Malawi, Uganda, Zimbabwe	Multi-country comparative study	Facilities	Interviewer administered survey, Record review	CPT
Chang [32]	2015	Uganda	Randomized trial	Patients	Survey-based assessment	CPT
Durovni [46]	2010	Brazil	Preliminary results of phased cluster randomized trial	Patients, Providers, Other stakeholders	Trial dataset record review, Interviews, Focus group discussion	IPT
Faust [47]	2020	Ethiopia, Nigeria, India, Angola, Brazil, China, DRC, Indonesia, Kenya, Lesotho, Liberia, Mozambique, Myanmar, South Africa, Tanzania, Thailand, Zambia, Zimbabwe	Survey	Countries	Survey (via email)	IPT
Gust [48]	2011	Botswana	Sub-study of the Botswana IPT prevention trial	Patients	Interviews, Focus group discussion, Interviewer-administered survey	IPT
Horwood [42]	2010	South Africa	Evaluation/ Cross-sectional descriptive study	Facilities	Record review, Survey-based interviews	CPT
Huerga [49]	2016	Kenya, Swaziland	Two prospective cohort studies	Patients/ Facilities	Record review (cohort study data, clinic registers), Interviews, Observation	IPT
Jacobson [50]	2017	South Africa	Qualitative study	Patients	Semi-structured interviews	IPT
Jarrett [51]	2019	South Africa	Multi-method assessment	Providers, Patients	In-depth interviews, Record review	IPT
Kamuhabwa [15]	2015	Tanzania	Retrospective descriptive study	Facilities, Caregivers, Providers	Record review, Interviewer-administered survey	CPT
Kamuhabwa [36]	2016	Tanzania	Descriptive cross-sectional study	Patients, Providers, Facilities	Record review, Semi-structured interviews, self-administered questionnaires, Focus group discussion, Facility assessment	CPT
Khan [52]	2014	South Africa	Diagnostic performance evaluation	Patients	TB screening questionnaire, Sputum specimens, Chest X-ray, Record review	IPT
Lai [53]	2019	Ethiopia	Cross-sectional study	Providers	Interviewer-administered questionnaires	IPT
Lester [54]	2010	South Africa	Qualitative methods study	Patients, Providers	In-depth interviews, Focus group discussion	IPT
Little [55]	2018	Malawi	Sub-study of the	Patients	Adherence (pills)	IPT

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

First author [citation]	Year of publication	Country	Study type	Study subjects	Data collection approach	Treatment of interest
			CHEPETS trial		dispensed at each visit), Interviewer-administered questionnaires	
Louwagie [37]	2012	South Africa	Historical cohort study	Facilities	Record review	CPT
Luyirika [40]	2013	Uganda	Retrospective case study	Facilities	Record review	CPT
McRobie [56]	2017	Uganda	Facility-level policy implementation assessment	Facilities, Other stakeholders	Key document review, structured health facility survey, Key informant interviews	IPT
Meribe [57]	2020	Nigeria	Assessment of a provider-focused intervention to increase IPT initiation and completion	Facilities	Review of routinely collected programme data, Health facility quality assessments	IPT
Mindachew [58]	2011	Ethiopia	Analytical cross-sectional study	Patients	Interviewer-administered structured questionnaires, Adherence (self-report)	IPT
Mugomeri [14]	2018	Lesotho	Qualitative study	Providers, Other stakeholders	Semi-structured interviews	CPT, IPT
Mugomeri [59]	2019	Lesotho	Retrospective cohort study	Patients	Record review	IPT
Munseri [60]	2008	Tanzania	Sub-study of the TB vaccine trial	Patients	Record review, Interviewer-administered questionnaires	IPT
Mwambete [35]	2013	Tanzania	Serial clinical and cross-sectional resistance study	Patients	Stool collection for resistance profiling, Adherence (self-report)	CPT
Naikoba [39]	2017	Uganda	Cluster-randomized trial	Providers, Facilities	Practical knowledge/competence assessment, Record review	CPT
Ngamvithayapong [61]	1997	Thailand	Prospective cohort study	Patients	Adherence (clinic attendance, pill count), Interviews, Focus group discussion	IPT
Okot-Chono [38]	2009	Uganda	Record review, qualitative study	Districts, Patients, Providers, Community members	Record review, Focus group discussion, Key informant interviews, In-depth interviews	CPT, IPT
Okwera [31]	2015	Uganda	Qualitative study	Patients	Focus group discussion	CPT
Reddy [62]	2020	India	Mixed-methods study	Patients, Providers	Review of routinely collected programme data, In-depth interviews	IPT
Rowe [63]	2005	South Africa	Record review, qualitative study	Patients, Providers	Record review, In-depth interviews	IPT
Selehelo [64]	2019	South Africa	Qualitative study	Patients	In-depth interviews	IPT
Sibanda [34]	2015	Zimbabwe	Qualitative study	Caregivers	In-depth interviews	CPT
Szakacs [65]	2006	South Africa	Adherence assessment, Cross-sectional study	Patients	Adherence (urine-metabolite testing, Interviewer-administered questionnaire)	IPT
Tram [66]	2019	Uganda	Cross-sectional study (sub-study of SEARCH HIV test and treat trial)	Patients	Record review, Interviewer-administered survey	IPT
Van Ginderdeuren [67]	2019	South Africa	Before-and-after study)	Facilities, Providers	Record review, Structured questionnaire survey	IPT
Wambiya [68]	2018	Kenya	Qualitative study	Providers	In-depth interviews	IPT

314 Abbreviations: CPT- cotrimoxazole preventive therapy; IPT – isoniazid preventive therapy, Providers – Healthcare providers or
 315 healthcare workers

316

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

317 **Risk of bias**

318 We assessed the methodological quality of each study individually (S7 Additional
319 file). First, we identified the categories of study design using the MMAT algorithm and then
320 appraised each study against the corresponding methodological quality criteria [21]. Among
321 all studies reporting findings for CPT and IPT, more than half (57%, 50%) applied
322 quantitative methods [15, 32, 33, 35, 37, 39, 41-44, 47, 52, 53, 55, 57-61, 65-67], followed
323 by studies that applied a combination of methods (21%, 28%) [36, 38, 40, 45, 46, 48, 49, 51,
324 56, 62, 63] and those that applied qualitative methods (21%, 18%) [14, 31, 34, 50, 54, 64,
325 68], for CPT and IPT, respectively. Across all studies that combined quantitative and
326 qualitative methods, most (80%) presented no methodological attempt to integrate phases,
327 results, and data from both streams of evidence [36, 38, 40, 46, 48, 51, 56, 63]. Therefore,
328 nine studies were categorised as multimethod studies [36, 38, 40, 46, 48, 49, 51, 56, 63] and
329 two as mixed methods studies [45, 62]. According to the MMAT checklist, many included
330 studies (n = 29) have methodological limitations in at least one of the quality criteria
331 evaluated. Qualitative studies (including the qualitative component of mixed methods and
332 multimethod studies) frequently failed to address and justify the qualitative approach applied
333 (e.g. ethnography, phenomenology) [31, 34, 36, 38, 40, 46, 51, 54, 56, 62, 63]. Quantitative
334 non-randomized studies frequently failed to address whether the intervention or exposure
335 occurred during the study period as intended [41, 43, 58-60, 66]. Some studies also missed
336 to provide reasons why certain eligible individuals chose not to participate [55, 60, 65].
337 Similarly, the risk of non-response bias was frequently not addressed across quantitative
338 descriptive studies [15, 35, 42, 47, 57]. Overall, many studies' research question(s) lacked
339 clarity and focus [32, 35, 38, 45, 56, 59]. We identified seven studies with methodological
340 limitations in more than two of the quality criteria evaluated [35, 38, 40, 45, 46, 56, 62].
341 However, to gain a broader understanding of the barriers and facilitators to PT's, we did not
342 exclude any study from our analysis regardless of the methodological limitations.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

343 Selective reporting of studies and findings in primary research may have introduced a
344 risk of bias across studies. Similarly, publication bias may have led to a systematic distortion
345 of our understanding of the phenomenon of interest, solely because specific findings are less
346 easily accessible or available. Bias introduced through studies or findings that are not
347 available (e.g. time-lag bias, truncation bias) could not be controlled. To address potential
348 biases that result from studies being less easily accessible or available, we highlighted the
349 absence of specific and relevant evidence in the limitation section of this review.

350 **Barriers to preventive therapies**

351 **Patient and community related barriers**

352 **Adverse reactions**, side effects or undesirable reactions were frequently assessed
353 in the included studies [14, 15, 31, 34-36, 46, 48, 53, 58, 60-64, 66-68]. Many of these
354 studies including two that based their findings on IPT trial data [46, 48] either found that both
355 preventive therapies were generally well tolerated, that the majority of patients had not
356 experienced any side effects, or both [15, 31, 35, 46, 48, 60, 63, 67]. However, we identified
357 the following adverse reactions among a minority of patients.

358 Regarding CPT, few patients reported itches and headaches [35], nausea and
359 vomiting [15, 35, 36], skin lesions or oral wounds [35], skin rashes [31, 35, 36], and
360 hypersensitivity reactions [15]. Additionally, heartburn, throat dryness, dizziness, fatigue,
361 appetite loss and numbness were reported by few HIV-positive adults [35]. In rare cases,
362 severe cutaneous reactions or burning sensations (e.g. Stevens-Johnson syndrome)
363 required therapy interruption [31, 36]. In this case, some received dapsone as an alternative
364 therapy for the prevention of opportunistic infections [31].

365 Regarding IPT, few patients reported headaches [46], arthralgia [46, 48], pruritus [46,
366 64], dizziness or fatigue [48, 62, 64], gastrointestinal disturbances [46, 62, 64], nausea or
367 appetite loss [48, 60, 62], vomiting [62, 64], weight loss [48] and darker skin complexion [64].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

368 The most serious, very rarely reported adverse reactions to INH were seizures, psychiatric
369 symptoms [48, 64], (peripheral) neuropathy [60, 62] and mild to moderate hepatotoxicity [46,
370 60]. Very few patients experienced adverse reactions that required therapy interruption [48,
371 60, 63]. After stopping IPT, liver function abnormalities resolved [60].

372 Co-administration of other drugs was believed to have contributed to adverse
373 reactions [35, 36, 48]. The simultaneous administration of ART, TB treatment and other
374 drugs (e.g. to treat hypertension, diabetes, asthma) was common among PLHIV [35, 36, 48,
375 64]. One patient reacted to concurrent CTZ and INH, two weeks after initiating ART [14].
376 Concurrent use of CTZ and nevirapine may have contributed to rash and leukopenia [36].
377 Besides, pyridoxine shortages and patients' poor nutritional status were believed to have
378 contributed to INH-associated neuropathies [62].

379 Our review revealed that side effects influenced patients' and health providers' views,
380 attitudes and practices regarding the use and prescription of preventive therapies. Some had
381 heard about side effects and feared experiencing such reactions in the future [31, 34]. Three
382 studies suggested that fear of potential side effects alone contributed to patients' non-
383 adherence to IPT [58, 60, 68]. However, seven papers also reported actual or perceived side
384 effects as the reason for patient-initiated non-completion or lacking adherence to IPT [58,
385 60-62, 66, 68] and CPT [36]. Tram and colleagues (2019) found that patients who reported
386 side effects, and those who believed INH was dangerous for their health had lower odds of
387 completing IPT [66]. Eventually, patients who stopped taking IPT may have discouraged
388 others from initiating the preventive therapy [68]. For IPT, side effects and contraindications
389 were also acknowledged by health providers [53, 62, 67]. For example, health providers
390 interviewed in rural India believed that side effects were an important reason for non-
391 completion of IPT [62]. Although health providers believed that IPT was important for PLHIV
392 [53], due to side effects and contraindications (e.g. active liver disease, history of adverse
393 reactions), sometimes the therapy was not prescribed [53, 67].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

394 Instead of discontinuing CPT, some patients independently reduced the prescribed
395 doses as a measure to manage side effects [15, 35, 36]. Parents reported reducing their
396 infants' doses of CTZ if they were unwell or perceived side effects [15]. Similarly, HIV-
397 positive pregnant women reported skipping doses of CTZ for the same reason or taking CTZ
398 at night to cope with perceived side effects [36].

399 **Lacking financial and organisational feasibility** frequently emerged as barrier
400 theme [15, 34, 38, 44, 46, 48, 50, 54, 58, 60-63, 65]. Evidence synthesis revealed that long
401 distance to the clinic [44, 60], lacking transport [15, 44], and the with transportation
402 associated costs [44, 46, 48, 50, 54, 63] routinely comprised an obstacle for patients to
403 access therapy and care. Women and adolescents were reported to lack control over
404 economic resources, leaving the decision to attend the clinic with their parents or husbands
405 [63]. Jacobson et al. (2017) [50] argued that a major barrier to IPT had been patients
406 entering HIV care. The researchers suggested that once linked to care (i.e. adherent to
407 ART), the marginal cost for patients to take IPT was low in the South African study setting
408 [50]. Our review found that frequent stock-outs at public health facilities caused therapy
409 interruptions among patients who could not afford to buy INH or CTZ at the community
410 pharmacy [15, 34, 38, 65]. Research from Uganda and Brazil suggested that TB screening
411 incurred additional costs for patients, including fees for chest radiology, transport for three
412 consecutive smear checks [46], as well as consultation fees [38]. HIV-positive clinic
413 attendees in South Africa frequently reported hunger and lack of food security. Lacking food
414 appeared to be a barrier to IPT because patients believed they could not take the therapy
415 without food intake [63]. Health providers in Karnataka, India, listed 'lack of social support
416 and access to social protection schemes' as a reason for patients' non-completion of IPT
417 [62]. In terms of organisational feasibility, studies from Botswana and South Africa showed
418 that patients were facing competing priorities, with the need to choose between spending a
419 full day waiting at the clinic, dedicating the time to their work [48, 50, 54] or addressing other
420 family members' needs [50, 63]. Studies from Ethiopia, Botswana, Uganda and Thailand

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

421 showed that patients did not access treatment or care, when they relocated [48], moved far
422 away [44] or were seeking work in other provinces [35, 50, 58, 61]. Parents and caregivers
423 reported lack of a refrigerator at home as challenge for storing paediatric formulations of
424 CPT [15].

425 **Knowledge gaps and misperceptions** regarding both preventive therapies were
426 barriers for patients' retention in care, therapy adherence and completion [15, 31, 38, 44, 48,
427 50, 51, 54, 61-64, 67, 68]. Patients in Uganda thought that CTZ is an analgesic drug, that
428 concurrent use of CTZ and ART, or TB treatment is contraindicated, and that CTZ was a
429 treatment for HIV-positive patients [31]. In Tanzania, parents and caregivers reported
430 difficulties in understanding how to use CPT. They particularly struggled to prepare the CTZ
431 suspension for their children using crushed tablets when the paediatric formulation was
432 unavailable [15]. Patients in Thailand thought that INH was prescribed to reduce HIV blood
433 concentration or prevent AIDS-related complications [61]. Patients in South Africa believed
434 that INH would alleviate symptoms, leaving asymptomatic patients unconvinced [50]. Three
435 studies reported that HIV-positive adults were not aware of the desired benefit of IPT in
436 preventing TB [50, 54, 61], and some patients had never heard of IPT [61]. Not knowing the
437 benefit, seemed acceptable for some patients, as shown in three studies, which revealed
438 that patients took IPT without understanding its purpose or duration [50, 61, 64]. However,
439 most studies suggested that low patient knowledge about IPT is rather harmful for its
440 implementation [44, 48, 50, 61, 63]. Knowledge gaps can create wrong assumptions,
441 mislead patients from the appropriate medical advice, or promote seeking information from
442 other sources [61]. Five studies reported insufficient patient information was a reason for
443 missing pills, therapy interruptions, or non-compliance to clinic appointments among PLHIV
444 [44, 48, 50, 61, 63]. Qualitative research conducted in South Africa revealed that some
445 patients interrupted therapy, thinking they no longer needed IPT when INH refills were
446 accidentally omitted [50]. This patient belief illustrates that knowledge gaps among PLHIV
447 also undermine patients' potential to generate demand for IPT [62]. Patients in Uganda and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

448 South Africa felt better and did not understand the need to return to the clinic, or to take IPT
449 when they did not have TB, suggesting they lacked understanding of the concept of
450 prevention [44, 51, 63]. Health providers interviewed in Kenya, South Africa and India also
451 acknowledged this problem [51, 62, 68]; some patients refused to take ‘TB medicine’ [INH]
452 without having TB [51, 68]. Others did not value the preventive effect of IPT because of the
453 low perceived risk of TB and lack of symptoms [62]. Health providers reported that
454 information materials were lacking or inadequate to educate PLHIV, suggesting there was a
455 lack of social campaigns, and consensus regarding patient education activities [62, 68].

456 **Patients’ lacking motivation** [15, 44] was identified for both preventive therapies
457 alongside with a number of explanations [15, 31, 34, 38, 44, 48, 54, 58, 62-64, 68]. Patients
458 reported they struggled with the need for too many clinic visits, on the one hand, due to a
459 lack of same-day services [38], on the other hand, due to the long waiting time prior to
460 receiving services [38], as well as the long preventive therapy duration [58, 68]. Patients
461 reported they were too busy to take IPT [44, 63] and also struggled with the daily pill burden
462 [31, 48, 54, 62, 64, 68], which was exacerbated through co-medication [54, 64]. Patients
463 revealed they received ART, medications for hypertension and diabetes, or asthma in
464 addition to IPT [64]. Pill burden affected patients adherence, providers believed [62, 68].
465 Some patients feared adding to the pill burden [62]; others completely declined to take IPT
466 due to the high number of pills prescribed to PLHIV [68]. Studies from Uganda and South
467 Africa reported that patients presumed side effects [44], found IPT unnecessary [63] or were
468 just not interested in taking IPT [44]. Research from Zimbabwe revealed that one mother felt
469 let down by pharmaceutical interventions and stopped giving CPT after her baby tested HIV-
470 positive [34].

471 **Forgetfulness** has been frequently reported as a reason for patients’ non-adherence
472 to preventive therapies [35, 48, 58, 65].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

473 **Patients’ HIV denial, religion and competing medicinal approaches** impeded
474 patients acceptability of preventive therapies [34, 36, 44, 48, 61, 63, 66]. Patients’ denial of
475 HIV was a barrier to patients’ retention in care [61], and consequently, their preventive
476 therapy uptake. Mothers who tested HIV-positive in Zimbabwe associated their diagnosis
477 with impending death and reported that they preferred to ignore HIV and not give CPT to
478 their babies when they felt depressed [34]. Non-compliant adult patients interviewed in
479 Uganda and Thailand were not accepting their HIV status and thus, never returned to the
480 clinic, or only months later [44, 61]. Research from Uganda suggested that after receiving
481 their test result patients were still in the process of coping with their HIV diagnosis [44].
482 Religion and competing medicinal approaches were barriers identified on the sub-Saharan
483 continent. Three studies suggested an influence of religion as an explanation for HIV denial
484 [36, 48, 63]. Interviews with HIV-positive pregnant women in Tanzania revealed that people
485 diagnosed with HIV were encouraged to pray that God will cure their infection, while born-
486 again Christians were advised to stop taking CTZ [36]. Self-reported reasons for non-
487 adherence and loss-to-follow up in the Botswana IPT trial also included religious beliefs [48].
488 In South Africa, a study participant who interrupted IPT reported that members of the church
489 could not combine clinic medication with church tea. Similarly, people believed it was
490 prohibited to take clinic medication with traditional medicines [63]. According to Rowe et al.
491 (2005), HIV was perceived as incurable by western medicine, while traditional healers were
492 perceived as able to cure HIV, suggesting two competing medicinal approaches [63].
493 Survey-based research conducted in Uganda found that among non-completers of IPT,
494 some patients took traditional medicines ‘to prevent becoming sick with TB’ [66].

495 **Stigma and fear of rejection or discrimination** remains a barrier for HIV care and
496 consequently for the implementation of both preventive therapies [34, 36, 38, 44, 48, 50, 60,
497 61, 63, 65, 66]. Cotrimoxazole and IPT were linked to HIV [36, 60, 63, 66], which although a
498 common infection in the countries included in this review, was frequently associated with
499 stigma and fear of rejection [34, 60, 63] or discrimination [48, 60, 63]. Studies found that

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

500 women feared separation from their spouses and families because of their diagnosis [34,
501 60]. Although mostly reported by women, in-depth interviews with HIV-positive mothers in
502 Zimbabwe, suggested that men also feared separation from their wives when testing HIV-
503 positive [34]. HIV-positive people were laughed at or ridiculed, suggesting a lack of
504 understanding of HIV within the community [34]. Among men, HIV was perceived as
505 emasculating [34]. These HIV-positive patients' experiences explain their frequently cited
506 unwillingness to disclose their HIV status [34, 36, 50, 60, 61, 63]. One study reported that a
507 woman disguised her HIV medication in a container for headache medication [50]. With the
508 intention to keep their diagnosis secret, it has been difficult for women to take CPT at their
509 crowded homes or administer it to their babies [34, 36]. Study participants in northern
510 Thailand did not allow nurses to visit their homes because they wanted to keep their HIV
511 status confidential [61].

512 The fact that patients feel the need to keep their HIV status confidential is a concern
513 because it is likely to contribute to the non-completion of preventive therapy. According to
514 Tram and colleagues (2019) [66], 'not talking to friends or family about IPT' was associated
515 with non-completion of IPT' while 'feeling comfortable taking IPT in front of a friend' was an
516 independent predictor for IPT completion among HIV-positive study participants in rural
517 Uganda. Lacking privacy and confidentiality at the health facility made it difficult for women
518 to hide their diagnosis [44]. People attending the overcrowded health facility took the risk of
519 being seen by their spouses and the community when collecting CTZ prescription refills [34]
520 or sitting in the open waiting area [38]. Fear of stigma within the household, caused
521 challenges to therapy adherence [58], whereas perceived at the health facility level, hindered
522 patients' retention in care [60].

523 **Influence of relatives and friends** may be an important factor for the
524 implementation of both preventive therapies [31, 34, 36, 44, 48, 60, 62, 63]. Although social
525 and family support seemed to positively influence some patients' therapy adherence [63],

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

526 compliance with the prescribed therapy regimen was at threat when patients lacked this
527 support [34, 44, 60, 63, 66]. Sometimes, relatives and friends adversely influenced patients'
528 compliance with their clinic appointments, retention in care, therapy adherence or
529 completion. Some patients felt discouraged by their relatives, who disapproved or sabotaged
530 their treatment adherence [31, 44, 48, 60]. Interviews with HIV-positive adults in Uganda and
531 Tanzania revealed that some had been discouraged by their spouse or relatives to take IPT
532 [44, 60]. Similarly, HIV-positive adults in Uganda were advised by their relatives to
533 discontinue CPT [31]. Interviews with HIV-positive mothers in Zimbabwe suggested that
534 some husbands opposed CPT. They refused to accept their wife's HIV status and treatment,
535 as well as the administration of CPT for their baby [34]. Research from Botswana reported
536 stolen pills, 'the boyfriend threw out the pills', or 'the sister flushed them down the toilet', as
537 reasons for trial participants discontinuation of IPT [48]. Some wives reported their husbands
538 stole their CTZ to take themselves [34]. Health providers in Tanzania reported that HIV-
539 positive pregnant women sometimes discarded CTZ, or shared it with their family members
540 [36].

541 **Socio-demographic, lifestyle and clinical factors** appeared to influence peoples'
542 use of IPT (i.e. their chances of initiating, receiving, completing or adhering to IPT) [14, 46,
543 48, 55, 58-60, 62, 66, 68]. Studies suggested that people's age (being younger) [48, 55, 59,
544 62, 66], low literacy or educational level [60, 62], their lifestyles [46], including drinking
545 alcohol [48, 62], negatively influenced patients' use of IPT. With respect to sex, we identified
546 contrasting findings; five studies suggested that being female was positively associated with
547 the use of IPT [48, 55, 59, 61, 62], while one study from Tanzania suggested vice versa [60].
548 Although there was some consensus that younger age was positively associated with the
549 use of IPT [48, 55, 59, 62, 66], some subgroups lagged behind. In particular, children (and
550 adolescents) had a lower probability of initiating (or receiving) IPT compared to their adult
551 counterparts [14, 59, 62]. Pregnant women (unaware of their HIV status) attending antenatal
552 care services as late as 36 or 38 weeks of pregnancy [14, 48], people aged over 65 [62] and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

553 spouses of PLHIV also lagged behind [14, 62]. A higher education level seemed to improve
554 the chances of IPT initiation [62] and completion [60]. A mixed-methods study from India
555 found that compared to those who were illiterate, patients with formal education had a higher
556 chance of IPT initiation [62]. The authors argued higher IPT completion rates among
557 participants with education above the secondary level could have been due to patients'
558 better understanding and comprehension of instructions [60]. Health providers interviewed in
559 Kenyan cities thought non-adherence was more likely across patients with a poor
560 immunological and clinical state and patients on second-line ART [68]. Similarly, results of a
561 retrospective cohort study carried out in Lesotho suggests that patients with WHO clinical
562 stage 4 were more likely to interrupt IPT than those with clinical stage 1, 2, or 3 [59]. Those
563 bedridden and with a poor clinical state may be interrupting IPT due to difficulties in reaching
564 the distant hospital [59].

565 **Concern about the efficacy of CPT** resulted from the steady evolution of antibiotic-
566 resistant bacteria. Research from Dar es Salaam, Tanzania, attempted to investigate the
567 incidence of faecal *E. coli* resistance to CTZ among HIV patients through in-vitro resistance
568 testing and found considerably high antibacterial resistance. The authors concluded
569 resistance concerns and suggested reconsidering the use of CPT in Tanzania [35]. Our
570 review also identified factors that may have contributed to the evolution of CTZ-resistant
571 bacteria. Factors presented by Okwera et al. include poor adherence to CPT and doctors'
572 loose prescription practices [31]. Besides, the availability of antibiotics without prescription
573 (in pharmacies, parks, or bus stations) may have promoted resistance to CTZ through
574 irrational use and self-medication [31, 35]. We did not identify resistance concerns or
575 scepticism about the continuous efficacy of CPT among health providers.

576 **Health provider related barriers**

577 **Shortage of health providers** working at public health facilities emerged as a barrier
578 for both preventive therapies [14, 36, 38, 43, 45, 46, 51, 56, 62, 64, 67, 68]. However, except

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

579 from one study that referred to CPT [36], all other studies reported staff shortages as an
580 obstacle for the implementation of IPT [14, 38, 43, 45, 46, 51, 56, 62, 64, 67, 68]. Shortage
581 of health providers was found in a range of countries including South Africa [51, 64, 67],
582 Uganda [38, 56], Kenya [45, 68], Tanzania [36], Nigeria [43], Lesotho [14], Brazil [46], and
583 India [62]. Regarding CPT, Kamuhabwa et al. (2016) [36] reported a shortage of
584 pharmaceutical personnel at the twenty-six antenatal clinics included in their study in
585 Tanzania. Regarding IPT, three studies from Uganda and Kenya explicitly stated health
586 provider shortages with few providers trained in IPT [68] or co-management of TB-HIV [38,
587 56], and altogether too few health professionals to implement HIV policies [56]. A
588 disproportional provider-patient ratio was reported, suggesting the number of health
589 providers did not allow the additional tasks required to deliver IPT [62, 64, 68]. Studies from
590 Brazil and Kenya, aimed at exploring doctors attitudes to IPT, described doctors' pressure to
591 see as many patients as possible (i.e. twenty to forty patients per provider before taking
592 lunch), thus indirectly reported provider shortages [45, 46]. Interviews with HIV and TB
593 doctors regarding their work, motivation and capacity to implement IPT in HIV clinics in
594 Brazil, showed that they were too busy, tense and solitary [46]. Although doctors interviewed
595 in Kenya believed in the importance of IPT for PLHIV, they found it difficult to manage TB
596 priorities among many other priorities [45]. Two studies from Uganda further advised that
597 working conditions (i.e. low salaries, heavy workloads) and missing incentives (i.e. career
598 development prospects) were demotivating for health providers, leading to high staff attrition
599 and consequently loss of knowledge [38, 56]. Similarly, research from South Africa reported
600 high staff turnover, which seemed to exacerbate the human resources challenges [67]. To
601 assess IPT completion rates among HIV-patients and determine predictive factors for IPT
602 completion, Adepoju and colleagues (2020) [43] carried out a retrospective cohort study that
603 included HIV-patients from six governmental hospitals in Nigeria. The study reported human
604 resources challenges in many hospitals and service delivery units. Similarly, a Ministry of

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

605 Health key informant said that staff shortage was a major challenge for implementing IPT in
606 Lesotho [14].

607 **Knowledge and training gaps** regarding both preventive therapies were identified among
608 health providers, limiting their ability to make appropriate therapy decisions [14, 36, 38, 39,
609 42, 44-46, 51, 54, 62, 68].

610 Regarding CPT, knowledge gaps existed among low and mid-level health providers
611 regarding the co-management of patients with HIV and TB [38, 39], CPT for malaria
612 prevention among HIV-positive pregnant women [36, 42], and CPT for babies born to HIV-
613 positive mothers [42]. Kamuhabwa et al. (2016) [36] applied multiple methods to assess CPT
614 implementation among HIV-infected pregnant women in malaria-endemic Tanzania after the
615 national policy had been changed from recommending sulfadoxine-pyrimethamine (SP)
616 intermittent preventive therapy to recommending CPT for malaria prevention in this patient
617 population. Although health providers perceived the new policy on CPT has been clearly
618 written and was understandable, they still did not have sufficient knowledge about the
619 inclusion criteria (HIV serostatus confirmed, time of initiation, no history of allergic reactions
620 caused by sulfur-containing drugs), and exclusion criteria (skin rashes, Stevens-Johnson
621 syndrome). The authors concluded that inadequate training was among the factors driving
622 poor implementation of CPT [36]. Task shifting is an important strategy to strengthen health
623 provider capacity; however, studies from Tanzania and South Africa have shown that lower
624 cadre required training to pursue their roles [36, 42]. Lay counsellors in South Africa
625 admitted they were undertaking tasks outside their scope when providing CTZ to babies [42],
626 while nurses in Tanzania dispensed medicines, including CTZ, without pharmacy training
627 [36].

628 Regarding IPT, knowledge gaps existed among HIV providers with various levels of
629 education, including doctors. Our evidence synthesis suggested that providers were
630 comfortable managing PLHIV [46], but lacked knowledge about TB [44, 46] and TB

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

631 prevention [14, 45, 46, 51, 54, 62, 68]. Interviews carried out with doctors specialized in HIV
632 in Brazil reported knowing the ART recommendations, but lacking knowledge about TB
633 prevention and co-management of (HIV and) TB [46]. One of the ten patients interviewed as
634 part of a multi-method assessment carried out in South Africa described being incorrectly
635 denied an IPT prescription; according to the interviewee, the nurse refused to prescribe IPT
636 because the patient did not have TB, suggesting knowledge gaps among nurses in the study
637 setting [51]. Other knowledge gaps identified were related to the target groups for IPT [14,
638 62], IPT duration [51, 68] and the assessment of IPT eligibility [14, 45, 46, 51, 62]. Two
639 studies revealed a lack of familiarity with IPT prescription requirements for children [14, 62]
640 and pregnant women [62]. One study found that of the twenty-two providers involved in IPT
641 prescription, not many knew that specific tablets were available for children (paediatric
642 dosage) [62]. Lacking clarity was identified about the role of chest x-ray when determining
643 IPT eligibility [45] and regarding the initiation of IPT without placing a TST [51]. Nurses
644 pointed out that although the national guidelines instruct them to prescribe IPT even if the
645 TST is out of stock, the guidelines state that a TST must be placed one month after IPT
646 initiation. Not knowing what to do if TST remained out of stock after IPT initiation, sometimes
647 prevented them from prescribing altogether [51]. Additionally, nurses were unsure how IPT
648 duration varied by patient age, TST result, pregnancy and ART status [51] and about the
649 period after which IPT should be repeated [14]. Research from South Africa revealed that
650 doctors lacked knowledge about the IPT guideline and were concerned about the need to
651 screen for and rule out active TB before initiating IPT [54]. Some health providers had
652 theoretical knowledge about the IPT recommendations [45, 51], but lacked experience or
653 familiarity in applying these guidelines in a clinical setting [45, 51, 54]. One nurse reported
654 she had never used a TST on a patient in her clinic and was unsure whether she could read
655 the result [51]. Lack of knowledge and familiarity with IPT among providers was explained by
656 inadequate staff education [14, 38, 45, 62, 68], and minimal follow-up supervision after
657 training [38]. Criticism was raised regarding the training modules provided to health

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

658 providers because they lacked content on TB-HIV collaborative activities [38], or included
659 limited or no specific training on IPT [68]. Consequently, providers felt inadequately
660 equipped to handle emerging challenges associated with IPT implementation [68]. Research
661 conducted in Lesotho by Mugomeri et al. (2018) [14], suggested that inadequate training has
662 been the main reason behind delayed IPT initiation in the study setting.

663 **Negative attitudes, concerns and fears** among health providers impeded the
664 delivery of IPT [14, 44, 45, 53, 54, 62, 64, 67, 68]. Our review revealed that health providers
665 often had a negative or sceptical attitude toward IPT, for which we found several
666 explanations [45, 51, 54, 62, 67, 68]. Providers perceived patients' irregular clinic
667 attendance, non-adherence to IPT and high loss to follow-up as demotivating and
668 discouraging for IPT initiation. Counselling patients about IPT and encouraging them to
669 adhere to preventive therapy was perceived as difficult and time-consuming [67]. During in-
670 depth interviews, nurses working in HIV care in South Africa expressed that patients
671 misunderstood or were unwilling to cooperate with an IPT prescription. In the absence of
672 external oversight (e.g. clinical mentorship), nurses would lose their motivation to prescribe
673 IPT interviews revealed [51]. Other factors that have discouraged providers from prescribing
674 IPT include discomfort with the long duration of IPT [68], the increasing workload [45, 68],
675 managing IPT among other priorities, and the influence of fellow health providers [68]. Two
676 studies reported that negative perceptions or doubts about IPT among some health
677 providers affected the perception and delivery of IPT by their fellow providers [54, 68].

678 Although evidence strongly recommends concomitant use of IPT with ART, research
679 from Lesotho suggests a general perception that HIV patients who are on ART for a long
680 time have a low-risk of developing TB. For this reason, providers mostly prescribed IPT to
681 patients newly diagnosed with HIV [14]. We also identified contrasting perceptions about the
682 effectiveness of IPT. Research from Lesotho stated that health providers perceived IPT was
683 effectively reducing TB disease among patients with HIV [14]. Meanwhile, a study from

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

684 South Africa reported health providers were unconvinced about the benefits of IPT [54].
685 Concerning was that consequently, health providers omitted to prescribe IPT in the South
686 African setting. Qualitative research carried out by Lester and colleagues (2010) [54] aimed
687 to explore patients' and providers' attitudes toward IPT. The study found that none of the
688 twenty HIV-patients interviewed had heard of IPT and doctors were either unaware of the
689 efficacy of IPT in preventing TB or believed the evidence was equivocal. Clinic staff and
690 doctors admitted that IPT was not part of routine practice (such as CPT); the authors
691 concluded that in this setting barriers to IPT were predominantly derived from health
692 providers [54].

693 Health providers' concerns and fears were related to active TB [14, 44, 64, 67, 68], antibiotic
694 resistance [45, 54, 64, 68] and side effects [14, 53, 68]. In the first place, health providers
695 were concerned about their ability to exclude active TB based on TB symptom screening.
696 Providers who worked in a setting where no TST was available believed that applying the
697 screening algorithm alone was insufficient to rule out TB [67, 68]. Atypical clinical
698 presentations complicated TB screening of patients coinfecting with TB-HIV [54], and
699 occasionally, HIV-patients developed TB disease during [44, 64] or after the course of IPT
700 [14, 44, 64]. Drug resistance was another concern of health providers which led to
701 scepticism about IPT [45, 54, 68]. Bacterial resistance to INH was believed to result from
702 providers' failure to rule out TB [64], periodic and long-term drug stock-outs [45], patients'
703 non-adherence to IPT [68] and the use of IPT in settings with a high prevalence of multi-drug
704 and extremely drug-resistant TB [54]. First, failure to rule out TB was revealed by Selehelo,
705 Makhado and Madiba (2020) who reported that health providers sometimes prescribed IPT
706 without symptom screening [64]. Their qualitative study applied in-depth interviews with HIV-
707 patients to explore their experiences regarding IPT provision and derive strategies to
708 improve IPT uptake in community health centres in South Africa. Patients interviewed
709 reported that symptom screening for active TB was not done before the provision of IPT and
710 that they developed TB while on IPT, regardless of reporting symptoms to the nurses [64].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

711 Second, health providers working in selected clinics in Kenya reported they were concerned
712 about contributing to drug resistance by exposing patients to IPT when INH stock-outs did
713 not permit therapy completion. If they were not confident all their eligible patients had 9-
714 months IPT supply providers preferred not to initiate IPT [45]. Third, health providers
715 interviewed in urban HIV clinics in Kenya expressed their concern that patients non-
716 adherence would lead to the development of resistant, multi-drug resistant or extensively
717 drug-resistant TB [68]. Fourth, health providers interviewed in South Africa expressed such
718 fear of inducing multi-drug resistance through INH monotherapy that some suggested
719 starting empirical courses of full treatment for TB. Providers believed a combination of drugs
720 was safer and offered greater benefit than INH monotherapy [54]. Eventually, some
721 providers feared that INH could induce side effects [14, 53, 68]. Overall, the fears and
722 concerns described made health providers feel uncomfortable or unwilling to prescribe IPT.

723 **Provider-patient communication** emerged as a barrier to the implementation of
724 IPT. Our review revealed that patients were often afraid to speak to health providers about
725 IPT, suggesting ineffective provider communication and a lack of trust in the health provider-
726 patient relationship [50, 51, 58]. Jacobson and colleagues (2017) [50] explored patients'
727 reasons for default from IPT through individual interviews. IPT defaulters stated that they
728 avoided reporting side effects, questioning missing medications, or requesting to re-start IPT
729 after treatment lapses, due to their fear of nurses scolding [50]. Research from Ethiopia
730 found that patients lacked advice from doctors, feared side effects and stigma [58]. The
731 authors concluded lack of provider-patient communication contributed to patients non-
732 adherence to IPT [58]. Similarly, HIV-patients interviewed in South Africa revealed that they
733 felt intimidated during their conversation with nurses; nearly half of them reported that nurses
734 were sometimes rude and that this discouraged them to ask about IPT [51].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

735 **Clinical information related barriers**

736 **Inaccurate recording and lacking integration of health records emerged as a**
737 barrier for both preventive therapies [14, 36-38, 42, 45, 51, 63, 67]. Although poor recording
738 of clinical information on patients' records was frequently reported [14, 37, 38, 42, 45, 67],
739 our review revealed that incomplete records did not necessarily imply that services have not
740 been provided [14, 37, 42, 45]. Horwood et al. (2010) interviewed HIV-positive mothers in
741 South Africa, regarding the health services and interventions their babies had received, and
742 compared this information with data recorded on the post-natal ward- and child health
743 records [42]. According to the mothers, significantly more babies had received CPT,
744 compared to what has been recorded on their health records [42]. Similarly, Lougwagie et al.
745 (2012) [37] reviewed altogether over two-thousand patient records from separate and semi-
746 integrated health facilities. Their study showed that CPT was less well recorded than
747 counselling and HIV testing, raising the question whether this was due to poor recording or
748 poor provision of the preventive therapy [37]. Van Ginderdeuren and colleagues (2019) [67]
749 obtained a similar pattern of results for IPT. Their record review showed a discrepancy
750 between what has been recorded by health providers in IPT registers and what patients had
751 received according to pharmacy records. The authors concluded underreporting of IPT in
752 routine IPT registers [67]. In line with this finding, Mugomeri et al. (2018) [14] suggested
753 underreporting of monthly statistics through the paper-based record system.

754 However, we identified weaknesses related to the health information systems
755 available to record patient data, contributing to inaccurate recording practices. First, health
756 information systems in many TB/ HIV high burden countries were paper-based or relied on a
757 mix of paper-based and electronic records [14, 45]. Research from Uganda described
758 recording tools were poorly designed and unpractical; HIV registers lacked data entry
759 sections regarding TB-HIV collaborative services, and TB information were only recorded on
760 patients' chronic care cards [38]. Similarly, Jarrett et al. (2019) [51] reported that patient

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

761 charts were disorganised and lacked a specific log for IPT registration, making it challenging
762 to track each patient's progress toward IPT completion. Most nurses discontinued IPT to
763 avoid the possibility of prescribing IPT past the intended duration, a study from South Africa
764 revealed [51]. Providers relied on a patchwork of documents completed by various team
765 members in a Kenyan study setting where patients did not see the same provider during
766 each visit [45]. The study reported that health providers frequently suffered from missing
767 patient data. In case patient data were missing, patient self-report was used to determine the
768 steps of TB diagnosis and IPT eligibility assessment previously completed. Doctors reported
769 they trusted patient recall over electronic medical record (EMR) data when patient
770 information conflicted [45].

771 Our review revealed that lacking integration of patient data recorded from different
772 service units bears two risks. First, documentation of patient data in separate patient files
773 (e.g. HIV registers, patients' chronic care card, laboratory-, pharmacy records) affected
774 service delivery efficiency by multiplying the time spent for document retrieval, data entry,
775 and in some cases the provision of services that had already been provided [38, 45].
776 Second, in the context of TB-HIV co-infection, poor recording, communication and lacking
777 service integration [36, 63] may lead to preventable drug interactions or adverse reactions. A
778 study from Tanzania reported that eight HIV-positive pregnant women were co-administered
779 both SP and CPT for malaria prevention, which is contraindicated because of increased risk
780 of severe cutaneous reactions [36]. Research from South Africa reported that four patients
781 whose clinical records suggested they were not eligible for IPT, had started the course [63].

782 **Ineffective monitoring, evaluation and surveillance** emerged as a second barrier
783 related to clinical information [14, 38, 56, 67]. Both concepts, monitoring and evaluation
784 (M&E) and surveillance require collecting data, that are analysed, and finally transformed
785 into strategic information that governments and leaders use to make informed decisions. We
786 identified weaknesses of the health information system and found that patient data recorded

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

787 at the health facility level were commonly inaccurate or lost [14, 45]. The detection and
788 notification of health events (surveillance) and reporting of routine programme data (M&E)
789 consequently leaked in its foundation.

790 In 2009, research from Uganda reported that no tools existed for routine recording
791 and reporting of TB-HIV surveillance data that permitted informing planning processes [38].
792 Eight years later, McRobbie et al. (2017) [56] reported that there were still no regional or
793 national information systems in place, that allowed the integration and submission of health
794 facility data in Uganda. Different views about obstacles for M&E in Lesotho were particularly
795 well described by Mugomeri et al. (2018) [14]. Through interviews with key informants, the
796 qualitative study found that major barriers to the implementation of IPT included ineffective
797 health information systems [14]. The representative of the WHO country office in Lesotho
798 warned that the IPT indicator system was paper-based and that data reported by health
799 facilities were inaccurate. One health provider acknowledged that the total number of
800 patients enrolled in IPT was unknown due to a shortage of paper registers [14]. The provider
801 added that monthly reports were sent to the MoH for congregate analysis, but feedback was
802 rarely received at the health facility level. The investigators confronted the responsible
803 ministry of health (MoH) representative who explained that it was not feasible to frequently
804 assess the effectiveness of their programmes and that their primary goal was to increase
805 IPT uptake. Providers were concerned that INH could induce side effects; some believed
806 that poor M&E resulted in the late detection of these undesirable reactions [14]. A partner
807 organization representative acknowledged the need for more resources, including stationary
808 and patient registers, and noted that failure to monitor patient referral, additionally
809 confounded monthly statistics [14]. A study from South Africa showed that IPT indicator data
810 were not comparable due to inconsistent denominators across health facilities. Some
811 facilities routinely collected data to measure IPT uptake among all PLHIV and others used
812 HIV-patients newly enrolled in HIV care as denominator [67]. Weaknesses identified by
813 Okot-Chono et al. (2009) [38] included that the existing supervisory visits carried out by

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

814 national and district officers for monitoring of the TB-HIV collaborative activities were
815 infrequent and had not been performed jointly by the TB and HIV programmes.

816 **Pharmaceutical management related barriers**

817 **Drug stock-outs or shortages** were common for both preventive therapies [14, 15,
818 33, 34, 36, 38, 45, 50, 51, 56-58, 62, 64, 65, 67, 68]. Except from one study that reported
819 stock-outs in India [62], all other studies reported stock issues in countries located in sub-
820 Saharan Africa. African countries included Kenya [45, 68], South Africa [50, 51, 64, 65, 67],
821 Uganda [38, 56], Tanzania [15, 36], Zimbabwe [34], Nigeria [57], and Lesotho [14].

822 Inconsistent drug supply, periodic and long-term stock-outs, or shortages of CTZ [14,
823 15, 33, 34, 36, 38] and INH [14, 45, 50, 51, 56, 57, 62, 64, 65, 67, 68] were obtained from
824 record reviews, reported by patients, health providers, representatives of MoH or partner
825 organizations. It may be noteworthy, that stock-outs were also reported for dapsone, an
826 alternative drug to CTZ [14] and pyridoxine, a drug prescribed to prevent peripheral
827 neuropathy caused by INH [14, 62]. Our review revealed consequences of and reasons for
828 the inconsistent availability of CTZ and INH.

829 Stock-outs of INH hindered therapy initiation [45, 56, 62], therapy adherence [64, 65]
830 and completion [62]. Interviews with doctors in Kenya showed that providers remained
831 hesitant to initiate IPT due to frequent pharmacy shortages [45]. Providers in Kenya
832 perceived stock-outs of INH and other supplies related to IPT as a major impediment to
833 effective implementation and acceptance of the therapy. Some providers felt the poor supply
834 of INH showed a lack of support for the IPT programme among policy-makers and
835 management. This, in turn, negatively affected their perception, morale and delivery of IPT
836 [68]. HIV patients interviewed in South Africa, reported medication stock-outs as the reason
837 for defaulting or not adhering to IPT [50, 65]. In-depth interviews with HIV-patients in South
838 Africa revealed that patients perceived the occasional unavailability of INH as inconvenient

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

839 and frustrating because it increased clinic visits and may lead to non-adherence [64]. One
840 study suggested that the location from which PLHIV collected their drug supply may have
841 predicted adherence to IPT, as peripheral pharmacies ran out of INH more frequently than
842 hospital pharmacies [65].

843 For CTZ, the included evidence suggested that drug shortages led to irregular uptake
844 of CPT [38], dose alterations among infants [15, 34], and patients skipping scheduled clinic
845 visits [36]. Stock-outs of CTZ at health facilities and HIV clinics were reported as the reason
846 why many children had missed one or more doses of CPT [14] and why only a few TB/HIV
847 co-infected patients received CPT regularly [38]. Studies from Tanzania and Zimbabwe
848 found that frequent shortages of the paediatric formulation at health facilities caused
849 challenges to caregivers and providers [15, 34]. In Tanzania, parents had difficulties
850 understanding how to crush tablets and prepare suspensions for their infants [15]. Lack of
851 CTZ at the health facilities was suggested as a reason for pregnant women skipping visits
852 scheduled at the antenatal clinics [36].

853 Among explanations to why health facilities and pharmacies frequently ran out of
854 CTZ, we found an increasing number of HIV patients [38], inaccurate recording [36],
855 challenges with quantification and forecasting of the prescribed preventive therapy [36, 38].
856 At the health facility level, we identified the late submission of health facility requisitions [38]
857 or ordering of drug quantities that did not cover the facility demand [36]. Outside the health
858 facility level, we found district-wide stock-outs of INH [51] and scarcity of CTZ at the medical
859 stores department or government supplier side [15]. A lack of support from policymakers,
860 programme management [14] or district health departments to adequately supply the lower
861 level units with medicines was also believed to facilitate stock-outs [38, 68]. A district health
862 officer interviewed in Uganda reported that it was not surprising that CTZ was not available
863 at the health facilities. Health offices failed to support lower-level health providers with
864 correctly quantifying drugs in stock and calculate drug consumption [38]. Ineffective supply

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

865 chain management [13, 35, 63, 65] and logistical challenges [58] provided alternative
866 explanations for frequent stock-outs. Finally, an uncoordinated implementation of IPT shown
867 by Meribe et al. (2020) [57] also led to long-term INH stock-outs. Their study reported a
868 strong focus on IPT at the beginning of the implementation process in Nigeria, which led to
869 the utilization of all stock at most sites, followed by national level stock-outs that lasted from
870 December 2018 to April 2019 [57].

871 **Lack of pharmaceutical personnel** emerged for both preventive therapies [36, 56].
872 Studies reported that sites in Uganda lacked a dedicated logistics manager [56] and that
873 health facilities lacked pharmacy personnel in Tanzania, where nurses without
874 pharmaceutical training dispensed medicines [36]. **Lack of written instructions** was
875 reported by Kamuhabwa et al. [36] referring to missing documented strategies for ensuring
876 the availability of CTZ at the health facilities on one hand, and missing written instructions
877 clarifying how medicines should be administered by patients at home on the other hand. The
878 authors suggested the need to provide patients with a list of known potential adverse
879 reactions, including those that require to stop taking the therapy [36].

880 **Service delivery related barriers**

881 **Sub-optimal service delivery** emerged as a critical barrier for the implementation of
882 both preventive therapies. We identified examples of sub-optimal service delivery in fourteen
883 studies that reported from a large range of countries with a high burden of TB and HIV [15,
884 34, 37, 38, 42-44, 46, 50, 51, 56, 62, 64, 68]. These examples primarily showed that service
885 delivery was time-consuming, the patient was not put at the centre of care and that health
886 services delivery was inefficient.

887 Service lapses, limited working days, and doctors' limited working hours have been
888 reported at public health facilities [44, 50]. A study from Uganda found that the AIDS
889 information Centre was closed when patients returned the first time after testing HIV-

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

890 positive; they never returned thereafter [44]. Studies reported that patients faced long
891 queues, spending hours waiting before receiving services or their medications [34, 38, 50,
892 64]. Jacobson et al. (2017) [50] reported that HIV patients endured long queues to collect
893 their medicines, often skipping meals and taking medications on an empty stomach [50].
894 Dispense of IPT and ART in separate lines [50] and the lacking synchronization of IPT with
895 other HIV clinic appointments [43] added to patients' waiting time and clinic visits. A
896 qualitative study explored women's ability to maintain their babies on CPT. The study found
897 that mothers typically had to dedicate the entire day to one clinic visit, which they found
898 difficult, considering they also had to attend the clinic for their own HIV care [34]. Due to lack
899 of same-day services, one family had to spend multiple days at the clinic for HIV care [34,
900 38], providing a possible explanation why only a few HIV-positive mothers in South Africa
901 reported attending regular follow-up for their own care [34], and why patients felt
902 discouraged. Overall, services delivery did not appear patient-friendly and routinely tested
903 patients' willingness and ability to receive HIV care [44]. Other examples of sub-optimal
904 service delivery showed weaknesses in the quality of healthcare provided.

905 Patient information, including tolerance to preventive therapy, side effects, drug
906 interactions, and therapy adherence, were frequently missing on patient records [14, 64, 66].
907 Some HIV-patients reported that their test results got lost at the health facility [50]. Interviews
908 revealed that HIV-positive mothers had received insufficient quantities of CTZ, lasting for
909 forty days, while their next clinic appointment was two months away [34]. Often, there was
910 no follow-up of HIV-patients who missed clinic appointments [15].

911 Among the potential underlying causes of sub-optimal service delivery, the disproportional
912 provider-patient ratio was the most prominent. Human resource constraints presented a
913 critical operational challenge to HIV services delivery [56, 62, 64]. As a result of MoH funding
914 constraints (and differing donor priorities), there were too few providers available to provide
915 necessary services [56]. It may be noteworthy that since the scale-up of HIV testing and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

916 ART followed by the universal treatment policy released in 2015, there has been an ever-
917 increasing number of PLHIV requiring continuous treatment and care. So far, the majority of
918 HIV services have been delivered at the health facility level, resulting in organisational and
919 operational challenges to handle the heavy patient load [15, 38, 40, 56, 62, 64]. For IPT, the
920 high patient load was believed to prevent nurses from screening every patient for IPT
921 eligibility [51]. Among other factors, IPT service delivery was believed to be greatly affected
922 by lack of integration between HIV and TB services [46], the inconsistent INH drug supply
923 [51, 62, 68] and inadequate records for IPT registration [51].

924 **Inadequate facility infrastructure** emerged as barrier theme for both preventive
925 therapies [15, 38, 56]. Health facilities in Tanzania lacked weighing scales to determine
926 infants' weight for CTZ doses calculation. Thus, providers based the doses on age rather
927 than weight, unable to ensure infants received the correct amount of preventive therapy [15].
928 Facility infrastructure has been reported as inadequate to ensure patients' privacy and
929 confidentiality; lacking counselling rooms and inadequate space to implement the HIV
930 policies was reported [38, 56]. Research from Uganda suggested that an outside waiting
931 area for HIV services attendees may raise suspicion among husbands seeing their wives
932 there seated, suspecting that she may have contracted HIV [38].

933 **Poor integration of preventive therapy-related services** was another important cross-
934 cutting barrier theme [14, 33, 36, 38, 42, 46, 50, 54, 56, 68] that arose from the segregated
935 delivery of health services in many high TB/HIV burden countries. Studies showed that
936 preventive therapies were frequently not part of the services provided at the health facility
937 [33, 42, 56]. Not all primary care facilities in Malawi and Uganda offered CPT for patients
938 with HIV on-site [33]. Only half of the immunization clinics in a South African study setting
939 provided CPT for HIV-exposed babies [42]. None of the twenty-four health facilities, included
940 in a study carried out in Uganda, offered IPT as service for patients with HIV [56]. Likewise,
941 research showed that additional testing services required before initiating IPT were also

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

942 frequently not available on-site [54, 68], which meant that for receiving preventive therapies,
943 patients had to attend other health facilities as well.

944 Overall, preventive therapy was poorly integrated with other speciality services [36, 38, 46,
945 50, 54, 68], often requiring patient referral between health facilities and incurring additional
946 patient costs [38, 68]. However, inter-clinic referral was reported to be weak [14, 38], added
947 to patients' costs [68] and challenged service quality [54]. In Kenya's capital HIV clinics,
948 most clinical examinations required before IPT initiation were carried out in separate
949 departments [68]. According to a study that was carried out in South Africa, only one of ten
950 clinics had onsite chest radiography, while none could test sputum on-site. Investigations for
951 TB performed off-site lacked coordination between TB and HIV shown in lost specimen and
952 laboratories not communicating TB test results with HIV sites. Lacking coordination between
953 TB and HIV sites was believed to hinder patients' initiation of IPT [54]. Poor inter-clinic
954 referral and separate clinic days for TB and HIV services were reported in Uganda,
955 demonstrating poor integration of IPT with HIV care [38]. Interviews with key informants in
956 Lesotho suggested that confirmation of patients' arrival at the referred centre was often
957 lacking [14]. Wambiya and colleagues (2018) [68] interviewed eighteen health providers in
958 urban Kenya to explore factors that influenced providers' acceptability of IPT. The study
959 reported that most clinical examinations were conducted in separate departments at
960 additional costs. Health providers urged that all testing services should be provided at the
961 same site. Costs incurred by additional exams should be subsidised to increase IPT uptake,
962 providers argued [68]. The need to refer patients to another facility for preventive therapy,
963 not only added to patients' waiting time and transport costs, it has shown to carry service
964 delivery related risks, such as dual administration of intermittent treatment for malaria
965 prevention in HIV-positive pregnant women. A study identified patients in Tanzania who
966 received both, SP at the antenatal care unit, and CPT at the Prevention of Mother To Child
967 Transmission (PMTCT) unit [36]. Research from Uganda reported that few TB patients were
968 tested for HIV, not identifying co-infected patients eligible for CPT [38]. In South Africa,

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

969 efforts have been made to integrate IPT-related services with ART services at the same
970 location. However, interviews with HIV-patients from four primary care health facilities and
971 one district hospital revealed that IPT and ART were dispensed in different queues and that
972 most facilities had not fully integrated TB and HIV services on-site [50].

973 **Patient loss to follow-up** was identified for both preventive therapies [42, 48, 55,
974 56, 62, 63, 67], referring to patients not linked to care (after HIV diagnosis) and those who
975 stopped attending clinic appointments. Mc Robie and colleagues (2017) [56] argued that
976 recent efforts in Uganda had focused on HIV testing and immediate ART provision without
977 strengthening health facility infrastructure and human resources accordingly to allow the
978 implementation of the complete set of HIV care policies. Consequently, systems failed to
979 maintain patients in care downstream in the care cascade, the authors concluded [56].
980 Besides difficulties to retain patients in care, engaging those reluctant to present for HIV
981 services (i.e. testing, care and support) from the beginning, also remained a challenge for
982 HIV service delivery [63].

983 A sub-study of the Botswana IPT trial explored self-reported reasons for trial
984 participants' loss to follow-up (LTFU) following IPT initiation. Reasons included patients'
985 financial and organisational feasibility to attend the clinic appointments, lacking motivation or
986 social support. Stigma, relocation, religious beliefs, and pregnancy also comprised reasons
987 for patients to stop preventive therapy, while some believed they had completed the study
988 [48]. We identified another example showing patients' loss to follow-up due to lack of linkage
989 to care, which can turn into a lost opportunity to provide CPT, as shown in a study from
990 South Africa. Coverage of PMTCT interventions was high during pregnancy and delivery, but
991 mothers and HIV-exposed infants were poorly linked to follow-up care after the baby was
992 born. The provision of CPT was also poorly recorded on the child health records. Follow-up
993 care (e.g. CPT and HIV testing of the new-born) therefore depended on the mother
994 reminding the health provider that their baby has been HIV-exposed. Less than half of the

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

995 eligible babies had a PCR test and initiated CPT at their first visit to the immunization clinic
996 [42]. Research suggests that patients' non-completion of IPT was frequently associated with
997 failure to return to the clinic for follow-up of IPT [55, 62]. Recent efforts have focused on
998 assigning health providers responsible for contacting these patients via telephone or in-
999 person. However, providers perceived that following-up of these patients was difficult and
1000 time-consuming [67].

1001 **Ruling out TB disease** has been reported as a major barrier to implementing [14,
1002 38, 45-47, 49-54, 62, 64, 67, 68]. Due to the need to rule out TB disease before therapy
1003 initiation and during the course of IPT, delivery of IPT has been perceived as difficult [53].
1004 Since 2011, WHO recommends using a simple algorithm to identify PLHIV unlikely to have
1005 active TB, no longer requiring other tests in countries where other tests are not available
1006 [13]. However, some countries continued using other recommended tools to determine
1007 patients' eligibility for IPT. According to a recent email survey [47], three different TB
1008 screening tools were used for PLHIV in high TB/HIV burden countries. Besides symptom-
1009 based TB screening (Kenya, Lesotho, Liberia, Myanmar, Nigeria, South Africa, Tanzania),
1010 tuberculin skin tests (Brazil, Ethiopia, Indonesia and Thailand) and interferon-gamma release
1011 assays (Ethiopia) have been used. Several countries reported combining screening tools
1012 (Brazil, Ethiopia, Indonesia, Kenya and Thailand). For example, Brazil reported using a
1013 combination of tuberculin skin tests (TST) and chest radiography, while Kenya reported a
1014 combination of symptom-based screening and radiography [47]. Evidence synthesis
1015 revealed several limitations for each screening tool.

1016 First, weaknesses of TST were frequently associated with the tuberculin (purified
1017 protein derivate) required to carry out the test. We identified shortage of purified protein
1018 derivate (PPD), delayed or insufficient supply from the manufacturers [47], challenges of
1019 ensuring the quality of PPD [47, 49], as well as the limited utility of TST in settings where
1020 BCG vaccination continued [47]. One study aimed to assess the acceptability and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1021 operational feasibility of TST in urban Kenya and rural Swaziland [49]. The study revealed
1022 that some health providers initially confused tuberculin with BCG vaccine. In both settings,
1023 some patients received an inappropriate amount (half-dose) of tuberculin injection. In rural
1024 Swaziland, cold chain monitoring issues were experienced [49]. Besides, the need for a
1025 second visit for TST reading was a major concern among patients and providers, implying
1026 additional time and transport costs [49, 67]. A questionnaire survey designed to identify
1027 barriers to IPT was administered to health providers in South Africa [67]. Survey findings
1028 showed that health providers had no time to perform TST; they found the TST reading time
1029 consuming and struggled to motivate patients to return for the reading [67]. Research from
1030 Brazil reported an alarmingly long time between the first clinic visit to IPT initiation. The time
1031 delay was explained by the fact that TST was not routinely offered in all clinics on all days
1032 and the chain of processes involved in TST. Once an asymptomatic patient received a
1033 positive TST result, chest radiography was required to rule out TB, for which the patient
1034 received a prescription. The patient then needed to schedule an imaging appointment before
1035 returning to the clinic to present the result to the doctor. Adding to the delays involved in the
1036 process of TST testing, patients may not have felt the urgency to quickly return to the clinic
1037 because they did not feel sick, the authors argued [46]. A review of patient records from five
1038 primary care health facilities revealed that only the facility that opted against TST reported a
1039 significant increase in IPT uptake [67]. Overall, the reported findings suggest that TST may
1040 have contributed to the low uptake of IPT [46, 47, 67]. At the time of our review, TST had
1041 been removed from most high burden countries' IPT policies. However, some countries,
1042 including Brazil, continued to apply TST as a necessary screening component [47].
1043 Proponents of TST argued that providing IPT only for those with latent TB infection (after
1044 careful exclusion of active TB) would avoid unnecessarily treating a significant number of
1045 patients that do not stand to benefit [49].

1046 Second, more recently developed interferon-gamma release assays (IGRAs) address
1047 important limitations of TST. Patients are only required to visit the clinic once for blood

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1048 collection and the result is available within one day. Additionally, prior BCG vaccination does
1049 not cause a false-positive IGRA test result. However, due to a lack of budget, lab
1050 infrastructure and trained personnel, and insufficient capacity for specimen transport, these
1051 relatively expensive tests have hardly been used in TB/HIV high burden countries [47].

1052 Third, symptom-based TB screening refers to a simple algorithm applied prior to
1053 initiating IPT and at every follow-up visit, thus allowing health providers to interrupt
1054 preventive therapy in case a patient develops symptoms of TB. Those who do not report any
1055 symptoms of current cough, fever, weight loss, or night sweats are unlikely to have active
1056 TB. If no contraindications to IPT exist, these patients should be offered preventive therapy
1057 [13]. Although symptom-based screening has significantly advanced IPT uptake in low-
1058 resource settings [53], we identified challenges associated with this approach.

1059 Challenges included doubts about the reliability of TB symptom screening among
1060 patients with HIV and TB-HIV, lacking provider capacity to routinely screen TB symptoms,
1061 and service delivery inefficiencies. Solely based on TB symptom screening, health providers
1062 found it difficult to rule out active TB [53] or decide whether a patient had active or latent TB
1063 [68]. Some providers believed that using the screening algorithm alone was insufficient to
1064 rule out TB [54, 67, 68]. Opponents of symptom-based screening argued that atypical clinical
1065 presentations complicated TB screening of patients coinfecting with TB-HIV who frequently
1066 suffered from extrapulmonary TB [54]. Khan et al. (2014) carried out a diagnostic
1067 performance evaluation among HIV patients in South Africa [52]. Study findings suggested
1068 that symptom-based screening was very sensitive and diagnostically useful among patients
1069 not on ART, however, less reliable among patients on ART [52]. The high patient load was
1070 believed to prevent providers from screening every HIV-patient for IPT eligibility [38, 51].
1071 During interviews conducted in South Africa, nurses repeatedly stated that staff shortages
1072 and the large patient burden prevented them from screening every HIV patient [51].
1073 Research revealed possible consequences of providers' lacking capacity to screen patients

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1074 for TB. Health providers either lose their motivation to prescribe IPT [51] or continue
1075 prescribing IPT without TB symptom screening [64, 67]. The latter was shown by Selehelo et
1076 al. (2019) [64]. The authors reported providers were prescribing IPT without screening for TB
1077 symptoms, which meant risking a delay of TB treatment and favouring the emergence of
1078 drug resistance [64]. We identified service delivery issues with symptom-based screening
1079 that delayed IPT initiation. Research from Lesotho [14] suggested that ineffective TB
1080 screening was due to an inefficient service delivery system. Delays in IPT initiation have
1081 been reported for patients with presumptive TB, indicating it took much time until TB was
1082 ruled out. The study also found that IPT was mainly initiated among patients newly
1083 diagnosed with HIV, while IPT uptake among patients enrolled on ART before IPT was
1084 launched in 2011 lagged behind [14]. Health providers interviewed in India reported that
1085 proxy attendance delayed IPT initiation. In the mainly rural study setting, patients often send
1086 their caregivers or other attenders to collect their ART refill, making it impossible for
1087 providers to assess patients' eligibility for IPT [62]. In Kenya, a combination of TB symptom
1088 screening and obligatory chest radiography was applied to determine HIV-patients' IPT
1089 eligibility [45, 47]. Doctors reported they were unsure about the steps to take to determine
1090 IPT eligibility. However, doubts were mostly related to the role of chest x-rays, when and if it
1091 should be ordered and how to read the radiographs [45]. Irrespective of the screening tool
1092 applied in each country, suspects of TB required additional investigation.

1093 **Investigation of TB suspects** is a crucial requirement for all patients with a positive
1094 TB screening result [13]. For those who developed TB during the course of IPT, additionally,
1095 drug susceptibility testing should be performed [52]. However, we identified several
1096 challenges associated with evaluating patients with presumptive and confirmed TB [14, 38,
1097 45, 49, 52, 54, 64, 67]. Diagnostic equipment needed to investigate TB included chest
1098 radiography [54], laboratory equipped for the analysis of sputum samples [45] and the
1099 identification of resistant TB strains [52]. However, the capacity to diagnose TB was limited
1100 in high TB/HIV burden countries, where most health facilities could not diagnose TB on-site

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1101 [52, 54]. Although the more accurate GeneXpert® test allows rapid diagnosis and
1102 identification of patients with drug-resistant TB, this expensive molecular test technology was
1103 often only available at centralised sites, reserved for a subset of complex cases [14, 45].
1104 Besides, our review revealed knowledge gaps among health providers related to co-
1105 management of TB-HIV [38] and their diagnostic competences [38, 45]. In Kenya, doctors
1106 specialised in HIV reported they were unsure how to read a chest radiograph [45]. Providers
1107 in Uganda reported struggling with the assessment of smear-negative and extra-pulmonary
1108 TB [38]. Most concerning was the study finding that only a minority of PLHIV with self-
1109 reported symptoms were investigated for TB [49, 67], causing TB treatment delays [64] or
1110 resulting in too many patients denied for IPT [49].

1111 **Health system financing related barriers**

1112 **Health system funding issues** were identified for both preventive therapies [14, 15,
1113 47, 56]. Many high TB/HIV burden countries historically depended on funding for HIV and TB
1114 from international donors and governments. Many will continue to require donor backing to
1115 improve the provision of a comprehensive care package to PLHIV [56].

1116 Lacking funds to purchase essential medicines (as which CTZ and INH are classified), has
1117 been reported in a Tanzanian study setting [15]. The quantitative descriptive study involved
1118 questionnaire-based interviews with health providers, who suggested lack of funds to
1119 purchase essential medicines at the health facility level had been an attributing factor for
1120 drug scarcity at public hospitals [15]. Similarly, qualitative research from Lesotho reported
1121 that among the main challenges for implementing IPT were interrupted supply chains caused
1122 by insufficient health system funding [14]. Through interviews with MoH key informants,
1123 health providers and representatives of partner organisations, the study found that additional
1124 resources were needed to sustain a seamless supply of drugs and reagents. A health
1125 provider reported that health facilities frequently ran out of CTZ, pyridoxine, and dapsone,
1126 among other drugs. Ministry of health officials expressed the need for health system funding

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1127 to be increased to improve the sustainability of HIV/ TB programmes, including IPT [14]. A
1128 recent email survey carried out by Faust et al. (2020) [47] aimed to identify challenges
1129 experienced in countries with a high burden of TB regarding the implementation of latent TB
1130 infection policies. Respondents from six high TB/HIV burden countries (i.e. Ethiopia, Liberia,
1131 Nigeria, South Africa, Tanzania, Zimbabwe) reported that guidelines existed, but due to
1132 financial barriers guidelines were not fully implemented [47].

1133 **Vertical funding** emerged as barrier theme for both preventive therapies [14, 38,
1134 56], referring to a stand-alone programme approach (e.g. HIV programme, TB programme)
1135 used in many resource-constrained countries for health system funding, typically associated
1136 with vertical governance and health service delivery. However, health system strengthening
1137 and the integrated provision of interventions that go beyond a single disease programme are
1138 not characteristic for vertical funding. Both preventive therapies are good examples for
1139 interventions that require some degree of collaboration between disease programmes (i.e.
1140 HIV, TB, PMTCT, child health) to ensure their successful implementation. Lacking funds for
1141 implementing TB/HIV collaborative activities in Uganda was reported on a national TB/HIV
1142 programme level and district level [38, 56]. Policymakers reported international donor
1143 dependency of the HIV programme [56]. Implementers and researchers interviewed about
1144 HIV policy implementation in Uganda reported misalignment of goals between the
1145 government and donors in determining priorities, suggesting lacking donor support for health
1146 systems strengthening and prevention activities [56]. Donors were considered to focus more
1147 on the provision of ART [56], while human resources constraints presented a critical
1148 operational challenge for providing HIV services, including IPT [14, 56]. However, funding of
1149 human resources primarily rested with the individual Ministry of Health [14, 56].

1150 **Leadership & governance related barriers**

1151 **Issues regarding policies and guidelines** emerged for both preventive therapies
1152 [14, 15, 38, 47, 51, 54, 67, 68]; however, were most commonly reported for IPT. A recent

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1153 survey [47] suggested that guidelines on latent TB infection (LTBI) did not exist in several
1154 high TB/HIV high burden countries (Angola, China, DRC, India, Indonesia, Kenya, Myanmar)
1155 [47]. Barriers to guideline implementation reported among these countries included
1156 prioritization of active TB over LTBI management (Angola, China, DRC, India, Kenya),
1157 financial barriers to programme implementation (Angola, DRC, Kenya), lack of programme
1158 staff (DRC) as well as guideline development still in progress (India, Indonesia, Kenya,
1159 Myanmar). The study suggested that in China, PLHIV were not targeted for LTBI treatment.
1160 However, the evidence relied not only on National TB programme staff but also on
1161 researchers and health officials. Findings, therefore, reflect the respondents' current
1162 knowledge and not necessarily the official situation in their respective countries [47].

1163 Preventive therapy guidelines were not always accessible [15, 38] and
1164 understandable for health providers [14, 15, 38, 51, 68]. Health providers in Tanzania
1165 reported no up-to-date guidelines were available at the health facility, hindering effective
1166 implementation of CPT for children born to HIV-positive mothers [15]. In Uganda, district
1167 officers had received policy guidelines on TB/HIV collaborative services but had not
1168 disseminated the documents to providers and communities [38]. In Kenya, South Africa and
1169 Lesotho, national guidelines for IPT were described as unclear [14, 68], ambiguous,
1170 confusing, and incomplete [51]. Lesotho's guideline was reported to lack clarity about the
1171 duration after which IPT should be repeated. Health providers noted that they were left with
1172 too much flexibility regarding the timing of IPT initiation. Some providers initiated ART before
1173 IPT to allow unmasking side effects of ART and ensure patients are stable. Others
1174 prescribed IPT only two weeks after ART initiation. This flexibility in the guidelines was
1175 believed to have contributed to the poor implementation of IPT [14]. Research from Kenya
1176 suggested that lacking clarity of IPT guidelines meant that providers struggled to implement
1177 IPT effectively. According to health providers from three HIV clinics in Nairobi, Kenya,
1178 particularly unclear were eligibility criteria and the duration of IPT, as well as how to decide
1179 whether a patient had active or latent TB [68]. Lacking clarity might have contributed to

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1180 health providers' low fidelity to the IPT guideline in South Africa [54, 67]. Van Ginderdeuren
1181 et al. (2019) [67] reported that across selected primary care health facilities, TST was not
1182 implemented as intended, symptomatic patients were not investigated for TB, and IPT
1183 initiation rate was generally low. Others have shown that, only in one out of ten sites
1184 included in their study, health providers prescribed according to the existing policy guideline.
1185 Providers seemed to lack clarity regarding the eligibility criteria for IPT. For example, some
1186 thought that IPT was indicated for patients with a CD4 count below 200 cells per microlitre,
1187 or reserved for patients on ART [54].

1188 **Lacking leadership and coordination** emerged for both preventive therapies [14,
1189 38, 42, 46, 50, 51, 68]. Both interventions require some degree of collaboration between
1190 disease programmes (i.e. HIV, TB, PMTCT, maternal and child health) to ensure their
1191 successful implementation. However, weak leadership and coordination at the strategic and
1192 operational level have been reported as a major challenge for TB/HIV collaborative activities
1193 [38, 46, 68]. Studies showed that TB and HIV services' responsibilities remained fragmented
1194 [46, 50] with lacking clarity concerning roles and responsibilities for collaborative service
1195 delivery at the health facility level [38, 42]. Research from Uganda found that it was not clear
1196 in the Ugandan study setting whether the responsibility for coordination belonged to TB or
1197 HIV health providers. With the exception of two health facilities, no coordination meetings
1198 had been held between the two programmes [38]. Mugomeri et al. (2018) [14] suggested
1199 that lack of leadership was among the major barriers to scaling-up IPT for PLHIV in Lesotho.
1200 Research carried out in two KwaZulu-Natal districts showed that PMTCT services were
1201 poorly integrated with maternal and child health services. Interviews with nurses and lay
1202 counsellors revealed a lack of clarity regarding their roles and responsibilities in the provision
1203 of CPT for HIV exposed babies [42].

1204 **Lacking top-down policy support and management issues** emerged as barriers
1205 for both preventive therapies [38, 50, 51, 68]. On an institutional and policy level, we

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1206 identified a lack of commitment, support and oversight as barriers to implementing IPT
1207 policies and collaborative TB/HIV activities. Providers interviewed in Kenya felt demotivated
1208 by the limited commitment at the policy level in ensuring effective implementation and
1209 streamlining of the IPT programme [68]. After investigating patients' reasons for defaulting
1210 IPT, Jacobson et al. (2017) [50] concluded that long queues, drug stock-outs, and a lack of
1211 service integration require attention on an institutional and policy level. At the health facility
1212 level, 'no-one was overseeing' the implementation of TB/HIV collaborative services,
1213 participants of a study conducted in Uganda reported. Inadequate joint supervision may lead
1214 to providers' poor performance, the authors suggested [38]. Similarly, in South Africa, nurses
1215 admitted that in the absence of external oversight, they would lose their motivation to
1216 prescribe IPT [51]. The multimethod study carried out by Jarett et al. (2019) [51] involved
1217 interviews with health providers after they had received a nurse-centred intervention. The
1218 intervention was designed to promote two target behaviours: checking IPT-eligibility for all
1219 PLHIV and prescribing IPT to this target population. The authors concluded that without
1220 adequate oversight, complicated guidelines would continue to hinder the implementation of
1221 IPT.

1222 **Inadequate planning** was identified as a barrier to the implementation of IPT and
1223 TB-HIV collaborative activities [14, 38]. Inadequate national planning was reported as an
1224 important barrier to IPT implementation in Lesotho, key informants said. Representatives of
1225 partner organizations reported that IPT was affected by lack of foresight at the planning
1226 stage and poor capacity to solve problems that arise [14]. Multimethod research from
1227 Uganda revealed that out of five districts implementing TB-HIV collaborative activities, only
1228 one had incorporated collaborative activities into its district work plan. The remaining four
1229 districts had separate HIV and TB plans that excluded TB-HIV joint activities. Another barrier
1230 to TB-HIV collaborative activities reported by the authors was that patients and communities
1231 were not involved in the planning process [38].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1232 **Lacking stakeholder engagement** emerged as a barrier theme for both preventive
1233 therapies, suggesting that community consultation and engagement of implementers and the
1234 population targeted for preventive therapies were insufficient, which may have hindered the
1235 scale-up of preventive therapies [14, 38, 68]. According to research from Uganda,
1236 community-related activities were planned without community involvement. Additionally, the
1237 study reported a lack of information flow from health facilities to the communities concerning
1238 the TB and TB-HIV services available [38]. The limited engagement of health providers in
1239 the development of the IPT guideline provided one explanation for their low acceptability of
1240 IPT in Kenya [68]. Health providers interviewed in Nairobi's selected HIV clinics reported
1241 they were told: "Here are the guidelines to be followed!". Providers felt they should have
1242 been involved in the process of guideline development [68]. Similarly, lacking engagement of
1243 the people responsible for implementing IPT (i.e. health providers) was reported to inhibit
1244 IPT uptake in Lesotho [14].

1245 **Metasummary**

1246 We summarised the identified barrier themes in tables and compared both preventive
1247 therapies with respect to similarities and differences of barriers (S8 Additional file). Overall,
1248 thirty-two barrier themes emerged from the comprehensive barrier description of which the
1249 majority were cross-cutting barrier themes (n = 25). We also identified seven intervention-
1250 specific themes.

1251 Barrier themes specific to CPT (n = 2) were 'concerns about the efficacy of CPT' in
1252 areas of high bacterial resistance [31, 35] and a 'lack of written instructions' (i.e. procedures
1253 to ensure the availability of CTZ and patient information) [36]. Barrier themes specifically
1254 identified for IPT (n = 5) include 'patients' socio-demographic, lifestyle and clinical factors'
1255 [14, 46, 48, 55, 59-62, 66, 68], 'providers' attitudes, beliefs & fears to induce INH resistance'
1256 [14, 44, 45, 51, 53, 54, 62, 64, 67, 68] and challenges related to 'provider-patient
1257 communication' [50, 51, 58]. Additionally, we identified issues with 'ruling out TB disease'

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1258 [14, 38, 45-47, 49-54, 62, 64, 67, 68] and ‘the investigation of TB suspects’ as intervention-
1259 specific barriers for IPT.

1260 After carefully grouping each barrier to the health system component from which it
1261 arose, we compared both preventive therapies with respect to similarities and differences of
1262 health system components most frequently associated with barriers. We found that barriers
1263 to both preventive treatments were most frequently related to ‘health service delivery’ and
1264 ‘patients & their community’. For IPT, health provider related barriers seemed to play an
1265 additional important role, third most frequently referred to. In contrast, barriers to CPT, were
1266 third most frequently related to ‘pharmaceutical management’. ‘Financing’ was among the
1267 health system components least frequently associated with barriers to either of the
1268 preventive therapies. We applied an innovative mapping technique to summarise the
1269 comprehensive barrier information. The resulting metasummary graphics illustrate all
1270 identified weaknesses (i.e. barrier themes) within each of the seven health system
1271 components, together with the number of papers that contributed information to each barrier
1272 theme. Therefore, mapping allows visual comparison of barrier themes identified for CPT
1273 (Fig 3) and IPT (Fig 4).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1274 **Fig 3. Metasummary: Barriers to cotrimoxazole preventive therapy for people living with HIV.** The graphic presents all main barrier themes identified in countries with a
1275 high burden of tuberculosis and HIV, assigned to the health system component from which the barrier theme arose, considering a seven component health system framework
1276 (modification of the WHO Framework for Action, 2010). Barrier themes identified in more than or equal to ten papers are presented with an exclamation mark. Numbers in
1277 brackets display the number of supporting papers. Total number of peer-reviewed papers included with barriers to cotrimoxazole in this review (N= 11).

1278 **Fig 4. Metasummary: Barriers to isoniazid preventive therapy for people living with HIV.** The graphic presents all main barrier themes identified in countries with a high
1279 burden of tuberculosis and HIV, assigned to the health system component from which the barrier theme arose, considering a seven component health system framework
1280 (modification of the WHO Framework for Action, 2010). Barrier themes identified in more than or equal to ten papers are presented with an exclamation mark. Numbers in
1281 brackets display the number of supporting papers. Total number of peer-reviewed papers included with barriers to isoniazid in this review (N= 28).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1282 **Facilitators for the implementation of preventive therapies**

1283 We identified a set of strategies for enhancing the health facility-based
1284 implementation of preventive therapies for PLHIV. We presented our findings, according to
1285 the preventive therapy cascade - a coding framework that we developed a priori (Fig 5).

1286 **Fig 5. The preventive therapy cascade.**

1287 TB - tuberculosis; HIV - human immunodeficiency virus; PLHIV- people living with HIV; IPT- isoniazid preventive
1288 therapy; CPT - cotrimoxazole preventive therapy.
1289

1290 The preventive therapy cascade outlines the steps that PLHIV repeatedly go through
1291 from having access to appropriate healthcare to completing preventive therapy. We
1292 developed this conceptual framework to promote stakeholder discussion about the ‘weak
1293 spots’ within the cascade in their specific setting. We listed the identified facilitators for the
1294 implementation of both preventive therapies accordingly. Therefore, this approach allows
1295 stakeholders (1) to select steps within the cascade that require attention, (2) to rapidly
1296 screen potential strategies that address these ‘weak spots’ within the cascade and (3)
1297 collaboratively choose a combination of strategies that are most appropriate in their specific
1298 context. For example, strategies to enhance patients’ adherence to PT’s are presented in
1299 section F6, shown in Fig 5. and Table 2.

1300 **Table 2. List of facilitators for the implementation of CPT and IPT.**

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F1 Access: Strategies for health system strengthening, improving access to and quality of health care

Leadership & governance

- Increase the number of health care facilities (especially in rural areas) [48, 60].
- Decentralised provision of preventive therapies (PT's) and related services:
 - at health centres rather than just hospitals [53, 62], at the community level (e.g. mobile radiology units) [45].
 - home-based care for selected patient groups (i.e. HIV+ pregnant women) [32, 36].
- Raising community knowledge & awareness about HIV & PT's (via education campaigns, health talks, initiatives [34, 64, 68]):
 - to reduce stigma, peoples' fears and misperceptions (e.g. reduce the 'emasculating' stigma of HIV through education messages that emphasise how treatment after testing HIV+ can help a man achieve his 'manly' roles by maintaining his health, allowing him to 'provide for the family') [34, 64].
 - to sensitise communities about HIV testing and CPT's benefits (e.g. malaria prevention during pregnancy, prevention of opportunistic infections among babies born to HIV+ mothers) [34].
 - to increase knowledge regarding the importance of IPT, its benefits and the purpose of taking it [64, 68].
 - consider incorporating IPT into the training curriculum of undergraduate students [64].
- Encourage companies to support employee health to reduce stigma at the workplace [34].
- Strong commitment and strategic implementation support from policymakers and health authorities [67, 68]:
 - National advocacy for IPT [68].
 - Stakeholder engagement: involving policymakers, higher level supervisors and health providers in the development of policies & guidelines, in the planning of resources for monitoring, the supervision and evaluation of outcomes particularly needed for the effective implementation of IPT [68].
 - Planning for policy implementation: according to the target dimension (e.g. piloting, large scale roll-out) and ensuring additional resources depending on the complexity of the intervention (e.g. CPT<IPT) [56].
- Monitoring & Evaluation (M&E) of the implementation [56]:
 - Clearly defined, standardised indicators to evaluate the implementation progress (i.e. IPT programme) [67].
 - Decentralised responsibility of M&E (e.g. long term external oversight from district level management) [51].
 - Need for (informatic) tools and skills for routine tracking of data (e.g. initiation, coverage) [59].
 - Sharing summary data with higher-level health authorities (district team, provincial team, MoH) [59].
 - Need for a well-defined feedback mechanism of reporting indicators [68].
 - Reflecting on results, adapting the implementation process if necessary [56].
- Ensuring national and regional policies exist on:
 - Stigma reduction strategies at the patient and community level (e.g. education about HIV, TB and the concept of prevention through teaching in schools, mass media, lectures on the radio, TV, skill building for potential perpetrators of stigma, involving peers) [34].
 - Strict policies for providers on patient confidentiality and supportive service provision [63].
 - HIV service integration (with TB care, family-, well-child- & maternal health care) [34, 37, 38, 40, 44, 46, 50].
 - Assessment of patients migration, travelling and relocation intentions and directions on how providers should proceed (e.g. clinic transfer, therapy prescription of >2months in advance) [50, 61].
 - Defining HIV service delivery strategy for vulnerable groups (i.e. commercial sex workers) [58].
 - Financial relief for PLHIV (subsidised transport to the clinic, free consultation, free treatment) [62, 63].
 - Social security benefits (e.g. disability grants for HIV/ AIDS, child support for caregivers of HIV+ children, nutritional support, food-partnerships with farmers, gardening or sustainable nutrition programmes) [63].
 - IPT policy modification and adequate dissemination [54].

Consider Policy update for IPT

- Considering (local, regional, national) lessons learnt for policy development of IPT delivery strategies [46, 63]
 - to identify specific target groups for scaling-up IPT (e.g. children and adolescents with HIV) [55, 59]
- Involving health providers in the development of the IPT guidelines to promote their agreement with IPT [68]
- Define set of minimum criteria to be met for IPT enrolment, such as:
 - Acceptance of HIV diagnosis [50] or openness about HIV status [63].
 - Adherent to other intensive treatment regimen (e.g. ART) [50, 63].
 - Regular clinic attendance (e.g. for at least 3 months or 4 visits) [63].
 - Counselling for patients newly diagnosed, or not yet on ART, before IPT initiation [50].
 - Requirement to attend support groups or linking HIV+ patients to community tracing [63].
- Allowing more time for patients to accept their HIV diagnosis before enrolment in intensive treatment regimen [61, 63].
- Simplifying and clarifying IPT policy [14, 51, 54, 67]:
 - Eligibility criteria; How to rule out active TB [54], role of chest radiography [54].
 - Consider using the WHO symptom screening algorithm (TST, chest radiography not mandatory) [47, 67].
 - Necessity to provide IPT together with pyridoxine [68]; monthly versus 3-monthly INH drug refills [68].
 - Health provider considerations before initiating IPT (e.g. clinical state, concurrent drug regimen) [68].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Strengthen clinical information systems

- Allocate resources to data collection, data recording and data management (e.g. data clerks, stationery items) [14, 45].
- Update and ensure the distribution of tools (paper-based or electronic) to record IPT and patient information [45].
 - Paper-based IPT monitoring tool (that allows recording patients' TB screening information prior to and upon IPT completion, side effects, documenting last drug pickup, refill periods [57].
 - Mobile application developed by WHO or adapting the app to local needs to improve recording of IPT [62].
 - Ensure tools allow efficient recording of patient information (e.g. integrated ART/ IPT registers and prescription forms) [14, 57], patient tracing between clinics and patient loss to follow-up [56].
 - Ideally one file held per patient in semi-integrated/ integrated facilities [37, 38].
- Improve reporting accuracy [67]:
 - Clearly written instructions to guide providers in recording of clinical data [42].
 - Conducting periodic surveys of patient cards to ensure the quality of routine recording [38].
- Consider the implementation of an electronic medical record (EMR) system if the following minimum system requirements are met: adequate data quality, reliable electricity, hardware & supplies, functional printers [45].
- Monitoring of risks (i.e. adverse reactions, drug interactions) and benefits of PT's [46, 50, 63].
- Monitoring of antimicrobial resistance [35, 52].

Pharmaceutical management

- Consider the authorisation of shorter TB preventive therapy regimen recommended by WHO [67, 68].
- Consider the use of ART/INH combination therapy in one tablet [64] or combined pre-packaging of ART and INH [43].
- Strengthen central procurement & supply chain management; Empower district TB office to procure INH locally [62].
- Consider authorising dispense of INH at referral centres closer to patients' homes [62].
- Considering potential peaks of INH demand (1. during scale-up, 2. when patients turn eligible for a repeat course) [57].

Service delivery considerations

- Patient-centred approach [66]:
 - Facilitate good and trusting health provider-patient relationship [50, 61, 63].
 - Ensuring patients' confidentiality (e.g. avoiding different queues or consultation rooms for HIV services at the health centre [64], or deliver HIV services separate from the general outpatient facility [34, 63].
- Empowering patients through knowledge and education [34, 48, 59, 63, 64]:
 - General information: living healthy with HIV, the concept of prevention and that PT is taken when asymptomatic [50]. TB risk and TB prevention [31, 36, 46].
 - Information about CPT [31]: Benefits - prescribed for preventing infections or 'to strengthen patients with low immunity', discouraging self-medication and pill sharing [35], importance of taking the correct drug amount, adherence to CPT during the prescribed duration [35], CPT can be used concurrently with ART and TB treatment [31], safety of CPT and potential side effects, side effects that require interruption of CPT, and that there is an alternative medicine (dapsone) [31].
 - Information about IPT [44, 46, 50, 58, 65]: Benefits, e.g. prescribed for preventing TB and not to alleviate symptoms [50, 67], importance of IPT [60], adherence to IPT, correct administration and duration of IPT [50], concurrent use with other treatments (e.g. ART), potential side effects (some treatable with pyridoxine), side effects requiring therapy interruption [50], encouraging reporting of side effects or complaints [50]
- Consider alternative approaches to deliver PT's:
 - TB/HIV service integration (requires close relationship between TB and HIV programmes, political will and considerable routine planning, coordination and monetary efforts [38, 44, 46, 55, 68].
 - 'Directly observed therapy' (DOT) approach for IPT [64].
 - Pharmacists delivering IPT (i.e. TB symptom screening, patient education, prescription and follow-up) [43].
- Develop patient education materials and ensure their distribution and availability at the health facilities [31].
- Consider establishing an initiative that engages patients' cultural, religious and spiritual beliefs (e.g. engage traditional healers to work alongside health providers in the clinic environment) [8].

Health system financing

- Financial commitment of Ministry of Health & donors [56] to fund HIV response [56], TB/HIV service collaboration [54].
- Additional funds needed for employment of health providers [14, 56], commodities and lab facilities [56].

Strengthen health provider capacity and knowledge

- Additional employment & shifting tasks to lower cadre to scale up HIV care and PT [15, 32, 38, 41-44].
 - Ensuring a reasonable patient-provider ratio [51], hiring personnel dedicated to IPT related activities [68].
 - Involving nurses [41], lay counsellors [42], pharmacists [43], social- and community workers [44], as well as PLHIV [32, 38] (i.e. peers, expert patients) to provide psychological support, PT, basic tasks, dispense tablets.
- Ensuring provider training & refresher training [14, 15, 36, 38, 42, 44, 46, 51, 53, 54, 66].
- Improving the working conditions of health providers (e.g. work environment, reduce provider workload) [67, 68].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F2	<p>Entry to health facility: Strategies to enhance patients' willingness and feasibility to enter public healthcare</p> <ul style="list-style-type: none"> • Welcoming and safe clinic environment, friendly and supportive health providers [63, 66]. • Making visits brief & convenient (i.e. offering all services on all clinic days, adding weekend clinic hours) [46, 48]. • Ensuring patients' confidentiality to reduce the fear of stigma/ discrimination [34, 42, 63]. • Encouragement & advice from peers (post -test club, support groups) [44, 63]. • No clinic consultation fees; no dispensing fees for patients with chronic diseases (i.e. HIV) [38, 63]. • Building incentives into service delivery (e.g. subsidized transport/ reimbursement, nutritional support) [60, 61, 63, 65]. • Family & community support and encouragement (emotional, financial, organisational support) [34, 50, 63]. • Consider integrating alternative medicine, church services, and family counselling into public health care if western medicine is not widely accepted (i.e. opposed by family, friends, church leaders, traditional medicine) [63]. • Providing patient information during pre-and post-test counselling [34, 44, 50, 60] or every clinic visit [36].
F3	<p>Eligibility: Strategies to increase health providers willingness and capability to determine patients' eligibility for PT's</p> <ul style="list-style-type: none"> • Empowering providers through training [14, 36, 38, 42, 44, 46, 51, 53, 54, 57, 62, 63, 66-68]: <ul style="list-style-type: none"> General information: <ul style="list-style-type: none"> - current epidemiology of HIV & TB [46, 53] and TB/HIV collaborative service provision [38]. - clinical particularities of TB/HIV co-infection [46], managing complex cases [39]. - current policies and guidelines regarding the treatment of latent TB, TB and HIV [51]. - public health importance of detecting and treating active TB among patients with HIV [46]. - How to facilitate nutritional support and social security grants [63]. - Communication skills (facilitating a good and trusting provider-patient relationship) [66]. Information on CPT: <ul style="list-style-type: none"> - CPT for HIV+ pregnant women [15, 36] and HIV-exposed babies [15]. Information on IPT: <ul style="list-style-type: none"> - Benefits of IPT [67], importance of IPT/ treating latent TB among patients with HIV [46, 51]. - Present current research consensus supporting IPT [46], showing IPT does not promote INH resistance [54]. - How to rule out TB and determine if patients are eligible for IPT. - Increase providers' confidence [53], capability [67] and motivation to prescribe IPT [67]. - Managing side effects and supporting patients to complete IPT [66]. - Difference between tuberculin and BCG vaccine (if applicable) and monitoring the tuberculin cold chain [49] • Measures to improve health providers' acceptability of IPT [68], their confidence and motivation to prescribe IPT: <ul style="list-style-type: none"> - Mentorship [51, 53, 57, 64], supportive supervision [46, 53, 57, 68] (e.g. from district level coordinators [51]), selecting and training an 'IPT champion' [51, 54], text messaging reminders of key criteria to determine IPT eligibility [51], ensuring a consistent supply of INH and pyridoxine [53]. - Involving local opinion leaders to change providers perception about IPT [48]. • Ensuring capacity for TB diagnosis & TB treatment essential for provision of IPT (i.e. adequate number of trained providers, facility infrastructure, ensuring a consistent supply of drugs) [14, 45, 53]. • Ensuring guidelines are well written, understandable and available at the health facility level [36, 53, 68]. • Ensuring routine evaluation and re-evaluation of patients' eligibility for IPT [43, 64]. • Availability of IPT recording tool (e.g. IPT register/ monitoring tool) [57]. • Tools to document IPT status (e.g. sticker reminder on patient file) [57]. • Tools to guide IPT decision making (e.g. paper-based work aid, or embedded electronic tool) [45].
F4	<p>Provision: Strategies to enhance health providers' prescribing practices of PT's (particularly IPT)</p> <ul style="list-style-type: none"> • Closing providers' knowledge gaps and enhancing their attitudes towards PT (particularly regarding IPT): <ul style="list-style-type: none"> - Educational campaigns & advocacy activities that include evidence basis and involve local opinion leaders, 'IPT champions' setting an example, prescribing IPT; positively influencing attitudes toward IPT [45, 46, 54, 66]. • Visible leadership, supervision and support of health providers: <ul style="list-style-type: none"> - Roles & responsibilities in PT provision clear [42, 63]. - Reinforcing national guidelines, provider encouragement by IPT champion and at weekly group meetings [51]. - One-on-one mentorship & supervision with feedback to support continuous skill acquisition and health providers' confidence to deliver tasks (e.g. ruling out TB, recording patient information, prescription of PT, prepare for- and managing side effects, treatment decisions for complex cases) [39, 46, 49-51, 53, 54, 67]. - Quality improvement approach to identify problems and take corrective action (teaching basic concept, routine data collection, chart analysis, weekly collaborative meetings to discuss successes and challenges) [57, 66]. - Quarterly site visits for record review (e.g. organised by district TB, HIV programme managers) [57, 64]. • Empowering patients to ask for IPT (e.g. posters and health education sessions at the health facility) [51]. • Review the process of PT delivery [49], tailoring it to the clinic routine [67], considering contextual challenges [68]: <ul style="list-style-type: none"> - Participatory approach (involving health providers) [49, 67], generation and use of data, lessons learnt [57]. - Consider reorganising services, improving patient flow within the clinic to avoid long waits [46, 56, 63].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F5	<p>Availability: Strategies to improve the availability of PT's at public health facilities and pharmacies</p> <ul style="list-style-type: none"> • Focus on ensuring the availability of CTZ and INH [14, 45, 50, 51, 64]: <ul style="list-style-type: none"> - Improving technical and logistic capacity at health facilities [68]. - Personnel responsible for inventory management, stock audits & the availability of stock at each level [45, 50]. - District level initiatives to improve INH availability (e.g. monthly monitoring of INH) [51]. - Improving supply chain management [14, 15, 45, 53, 57, 68]. - Implementing a stock inventory management system [36], detailed accounting of stock supplies at all levels [45]. - Quantification and demand forecasting [36]; include back-up stock (additional buffer) [45]. - Routine stock audits to identify & address INH stock-outs at health facilities and pharmacies [65]. - Developing stock capacities centrally, decentralised and at the health facility level [33, 45]. • Health facility approach for insufficient stock: <ul style="list-style-type: none"> - Prioritising patient subgroups (e.g. based on CD4 count, compliant with clinic visits, adherence to ART) [62]. - Earmarking drugs for a full course of IPT (e.g. 6-months) for each patient who initiated IPT [57, 62]. • Health facility approaches in case of stock-outs: <ul style="list-style-type: none"> - Informing patients about stock-outs to avoid confusion (e.g. patient may think he/she completed PT) [50]. - Prescribing alternative formulation of CTZ/ INH (e.g. tablets instead of suspension for children) [15]. - Advising patients to return when stock is available [15] or buy CTZ/ INH in private pharmacies [15, 35, 36, 38].
F6	<p>Adherence: Strategies to enhance patients willingness and feasibility to adhere to PT's</p> <ul style="list-style-type: none"> • Individual assessment of patients' needs, concerns and feasibility to initiate IPT: <ul style="list-style-type: none"> - Consider initiating IPT at the time of HIV diagnosis [55]. - Need for providers to discuss patients' feasibility of (e.g. monthly) clinic visits, and offer PT based on individual assessment of patient's needs, concerns and commitment to follow clinic visits [15, 50, 61]. - Discussing patients' travel plans (e.g. consider prescribing >2months of IPT for patients who will travel [50]. - Facilitate clinic transfer between different cities/ provinces or allow treatment supply in advance [50]. • Allowing more time before enrolling patients into intensive treatment regimen (if policy & guideline allows) [44, 63]. • Educating patients before initiating IPT [64]: <ul style="list-style-type: none"> - Risk of developing TB, importance of IPT, side effects; dapsons, pyridoxine to manage side effects [31, 50, 64]. - Encouraging patients to report problems or complaints [50], support patients in managing side effects [64]. - Encourage patients to disclose HIV diagnosis to a trusted person or family member [63]. • Health facility support services: <ul style="list-style-type: none"> - Support groups, nutritionist, food parcels, multivitamins [63], transport support [62, 63]. - Couple testing [34], Involvement of partner/ friend during initiation of IPT; ensuring family approval of PT [34, 60]. • Patients' adherence support: <ul style="list-style-type: none"> - Social support or feeling comfortable taking PT in front of others [34, 36, 40, 60, 66]. - Reminder systems developed by patients (e.g. phone alarms [34, 61], marking a calendar [61]). - Adherence club member collects ART and INH for the group members [64]. • Health facility-based adherence support: <ul style="list-style-type: none"> - clinic visit reminders or follow-up by health providers (e.g. through phone calls, home visits to follow up and encourage defaulters/ community tracing) [36, 44, 53, 61, 63]. - Adherence assessment (patient self-report, pill counts during treatment refills, INH metabolite testing) [36, 65]. - Provider encouragement and follow-up to adhere to PT [53, 64].
F7	<p>Retention in care: Strategies that encourage patients' completion of PT</p> <ul style="list-style-type: none"> • Patients self-motivation: <ul style="list-style-type: none"> - Belief that PT is useful improves health status or is important to prevent disease [31, 34, 50, 60, 64, 66]. - Belief in personal health threat or fear of disease (e.g. concern about family) [34, 61]. - Belief in the effectiveness of health care, understanding the importance of PT's. • Acceptance of HIV status, disclosure to supportive person, comfortable to take PT in front of others [58, 61, 63, 64]. • Reducing patients' need to travel to multiple clinics: <ul style="list-style-type: none"> - Same-day appointments for family members [34]. - HIV service integration with other services (e.g. providing ART + IPT; TB treatment + CPT at the same time and location) [38, 43, 46, 50, 68]. • Reducing patients' frequency of health facility visits and medication pickups: <ul style="list-style-type: none"> - Differentiated care: e.g. quarterly clinic attendance for clinically 'stable' PLHIV [50, 66]. - Home visits or home-based care (with health facility referral of complex cases) [36, 66]. - Adherence club member collects ART and INH for the group of members [64]. • Positive attitudes of health providers or good provider-patient relationship [64]. • Patient follow-up or linking HIV+ patients to community tracing in case they miss clinic appointments [53, 63].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1301 **Discussion**

1302 In high TB/HIV burden countries, both preventive therapies in the centre of this
1303 review (i.e. CPT, IPT) are key interventions for PLHIV that can save lives if administered
1304 together with ART, or even on their own [6, 9]. However, governments of high TB/HIV
1305 burden countries face major implementation challenges that limit the effectiveness of both
1306 preventive therapies [16-18]. We explored and compared both preventive therapies with
1307 respect to similarities and differences of barriers identified across high TB/HIV burden
1308 countries published in peer-reviewed literature. Additionally, we explored and summarised
1309 strategies (facilitators) with the potential to tackle the identified barriers.

1310 **Similarities and differences in barriers**

1311 Detailed barrier description presented in this review offered various explanations to
1312 why the implementation of both preventive therapies has been so challenging in the
1313 concerned countries. However, careful analysis of the extracted barrier information showed
1314 that many barriers were very similar for both preventive therapies. Our metasummary
1315 findings showed that the majority of barrier themes (25/32) that emerged from this review
1316 were identical for CPT and IPT and thus not intervention-specific (Figs 3 and 4). This leads
1317 to the question: "What are the underlying patterns of these cross-cutting barrier themes?"
1318 Taking into consideration that cross-cutting barrier themes were scattered across all building
1319 blocks of the health system and rather generic in nature indicates that systematic
1320 weaknesses within the health system may be an important underlying reason for
1321 implementation struggles. All barrier reporting studies (N=37), except one [52], reported
1322 such cross-cutting barriers, which at least hints that many high TB/HIV burden countries'
1323 health systems were weak and unable to meet the basic requirements of a well-functioning
1324 health system [27]. Fragile public health systems could be explained by the fact that more
1325 than three-quarters of the countries with a high burden of TB and HIV are low- and lower-
1326 middle-income countries (as per 2021 World Bank's classification) [69]. Many of these

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1327 countries have severely constrained health budgets and historically depend on foreign
1328 assistance [70]. Following two decades of increasing domestic and generous international
1329 funding that has been mainly channelled into vertical health programs, impressive gains
1330 have been achieved in reducing AIDS-related deaths [27]. However, health systems
1331 strengthening is not characteristic for vertical funding and healthcare organisation. A major
1332 concern is that impressive gains of the past have been neither universal, nor sustainable
1333 [27]. We speculate that the sustainability of the HIV response and health facility-based
1334 delivery of both preventive therapies will become more challenging over the next years. The
1335 dilemma is that funding from international donors is flatlining [70], while an increasing
1336 number of HIV patients require life-long medical care [71] to be delivered by vertical
1337 programs that have long reached the limit of their effectiveness. Others have claimed that
1338 strengthening weak public health systems in the developing world is the next 'emergency'
1339 and an inevitable step to sustain the progress achieved in the last two decades [72]. At this
1340 stage of understanding, we believe it is quite possible that health system constraints
1341 identified for CPT and IPT, similarly hinder the implementation of other health facility-based
1342 interventions in high TB/HIV burden countries. Therefore, in addition to intervention-specific
1343 barriers, context-specific health system constraints should be considered to move towards a
1344 more feasible implementation strategy.

1345 Like for CPT, barriers identified for IPT were most frequently classified as 'service
1346 delivery-' or 'patient & community related'. Typically, 'service delivery related barriers' were
1347 interrelated with constraints identified across other health system components. For instance,
1348 with inaccurate clinical information, insufficient health providers and frequent drug stock-
1349 outs, efficient and reliable delivery of preventive therapy is unrealistic. These interrelations
1350 highlight that service delivery strongly depends on a well-functioning interplay of the health
1351 system components represented in the original WHO's Framework for action [27]. We
1352 observed that barriers identified across the six original health system components (i.e. health
1353 workforce, information systems, essential medicines, financing, leadership/ governance,

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1354 service delivery) represented constraints on the supply side. Meanwhile, 'patient and
1355 community-related barriers' comprised limitations that limited the demand of preventive
1356 therapies, hindering patients from entering healthcare, leading to inconsistent clinic visits or
1357 therapy interruptions. Among all 'patient and community-related barriers', we would like to
1358 draw special attention to 'lacking financial and organisational feasibility'. This barrier theme
1359 was supported by more than one third of all studies included in this review [12, 15, 16, 22,
1360 23, 25, 28, 31, 40-45], suggesting that in resource-constrained countries and in the context
1361 of poverty, free provision of health facility-based services may not be sufficient to ensure
1362 equitable access to healthcare. The economic impact of COVID-19 is expected to further
1363 decrease patients' average household income in the coming years, posing an increasing
1364 threat to their ability to commit to frequent health facility visits and medication pickups.
1365 Summarising the above, barriers to both, CPT and IPT were most frequently classified as
1366 'service delivery-' or 'patient & community related', representing supply- and demand-side
1367 constraints that introduce complex, interrelated dynamics [73]. Therefore, we emphasise the
1368 value of a 'seven component health system framework' for the purpose of barrier exploration
1369 and the formulation of an implementation strategy that is tailored to address potential
1370 barriers on the supply- and demand-side.

1371 We also revealed some differences between barriers to both preventive therapies.
1372 Overall, our review suggests that implementing IPT has been more troublesome than CPT,
1373 supported by overall more barrier themes and evidence reporting barriers to IPT. This is
1374 consistent with the cross-sectional study carried out by WHO HIV/AIDS programme officers
1375 in 2007 [74], which showed that less progress had been made in implementing IPT when
1376 compared to CPT at the time. Thus, more research focus may have been on IPT since.
1377 Nevertheless, we argue that there is also more complexity involved in the eligibility
1378 assessment and provision of IPT compared to the more straightforward provision of CPT.
1379 Implementing IPT requires a higher degree of coordination; its delivery involves multiple
1380 steps, requires particular skills and seems to depend on additional capacity (particularly

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1381 human resources) to follow-up patients who initiated IPT and those with a positive TB
1382 screening result.

1383 Considering challenges specific to implementing IPT, 'health provider related barriers'
1384 appeared to play an important role. Our review revealed that having to rule out active TB
1385 disease was an important issue for the implementation of IPT. First, local policies and
1386 guidelines were described as unclear, so that health providers lacked knowledge and
1387 confidence in determining who is eligible for IPT [14, 68]. Second, health providers appeared
1388 to be overwhelmed with this additional task of routinely assessing and documenting patients'
1389 eligibility [38, 51]. Third, while health providers attitudes towards CPT seemed neutral or
1390 positive, providers' attitudes and beliefs toward IPT were partially negative [14, 44, 45, 53,
1391 54, 62, 64, 67, 68]. One health provider concern was that extrapulmonary TB, common
1392 among PLHIV, may go undetected when screening for pulmonary symptoms [54]. Some
1393 health providers appeared to be unconvinced whether the benefits of IPT outweigh the risks
1394 of side effects [14, 53, 68] or of promoting INH resistance [45, 54, 64, 68]. Studies carried
1395 out in sub-Saharan Africa reported that some health providers had refused to prescribe IPT
1396 because of their fear of promoting INH resistance [54]. Overall, the use of preventive
1397 therapies has often been controversial, with concerns about drug resistance forming one
1398 major barrier to policy development and implementation [75]. However, it was somewhat
1399 surprising that studies reported health providers' concern about bacterial resistance for IPT
1400 [45, 54, 68], but not for CPT. Notably, many high TB/HIV burden countries witness a high
1401 burden of MDR-TB [2]. Instead of INH monoresistance, health providers' genuine concern
1402 may thus lay in promoting MDR-TB among patients with HIV [54]. Another surprising barrier
1403 theme identified specifically for IPT was provider-patient communication [50, 51, 58], which
1404 could indicate that communication needs are greater for IPT. However, only three studies
1405 reported issues with provider-patient communication regarding IPT [50, 51, 58]. Therefore,
1406 this barrier could also be indicative for changing patient expectations. A popular explanation
1407 is that the patient-provider relationship has changed over time. Health providers are no

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1408 longer seen as the dominant decision-makers and patients as passive service recipients (i.e.
1409 paternalistic model) [76]. Instead, patients expect and are expected to be actively involved in
1410 their therapy decision [76]. Based on our review findings, patients were often afraid to speak
1411 to health providers about IPT [50, 51, 58], suggesting that providers may require additional
1412 training in how to develop a trusting provider-patient relationship and encourage their
1413 patients to address any arising concern. With the increasing global interest in TB prevention
1414 [2], several studies have been dedicated to assessing socio-demographic, lifestyle- and
1415 clinical factors associated with HIV patients' chances of initiating, receiving, completing or
1416 adhering to IPT [14, 46, 48, 55, 58-60, 62, 66, 68]. These studies highlight key populations
1417 that may benefit from tailored implementation approaches. Another important factor for the
1418 implementation of IPT is that, in contrast to CPT, IPT requires greater coordination between
1419 HIV and TB program at all levels. Many high TB/HIV burden countries have implemented
1420 symptom-based screening to determine patients eligible for IPT [47], which is believed to
1421 have significantly advanced IPT uptake in low-resource settings [53]. On the one hand,
1422 symptom-based screening enabled HIV services units to take greater responsibility for
1423 implementing IPT. However, findings of the studies included in this review suggest that TB
1424 services' capacity and linkage was too weak to follow-up patients with presumptive TB and
1425 to ensure immediate TB treatment for patients with confirmed TB [14, 38, 45, 49, 52, 54, 64,
1426 67]. This leads to another challenge that is particular for IPT; it requires collaboration and
1427 capacity for the co-management of TB.

1428 Considering challenges specific to the implementation of CPT, we found that
1429 bacterial resistance was a concern raised by the authors of a study included in our review
1430 [35]. Mwambete and Kamuhabwa (2016) questioned the efficacy of CTZ in areas of high
1431 bacterial resistance as a result of their research findings. Based on the disk diffusion
1432 method, their study identified an overall high resistance of isolated enteric *E. coli* among HIV
1433 patients in Tanzania [35]. Although antimicrobial resistance is a topic of utmost urgency,
1434 there are reasons to doubt the urgent need to reconsider the use of CPT in high TB/HIV

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1435 burden countries. On the one hand, the in-vitro assay applied in the study [35] is no longer
1436 the gold standard for antimicrobial susceptibility testing because it often disqualifies
1437 antibiotics that are, in fact, effective in-vivo [77, 78]. On the other hand, several studies have
1438 shown significant reductions in morbidity and mortality among PLHIV on CPT, despite the
1439 fact that they were carried out in settings with high bacterial resistance. Therefore, others
1440 have argued that in-vitro resistance testing undermines the prophylactic ability of CTZ [79].
1441 Finally, one study included in our review suggested a lack of written instructions for patients,
1442 referring to missing documented strategies for ensuring the availability of CTZ at the health
1443 facilities and patient leaflets that list potential adverse reactions that require therapy
1444 interruption [36]. Although we revealed several knowledge gaps and misperceptions among
1445 patients in our review that could be addressed in written instructions, the provision of patient
1446 information leaflets, in general, is not yet standard practice in many low- and middle- income
1447 countries [80]. One popular explanation for the under-utilisation of information leaflets at
1448 public pharmacies is that they are poorly understood [81]. Poor understanding may be more
1449 pronounced among populations with low literacy, which may have led to low prioritisation of
1450 creating such written information in the concerned countries. However, in combination with
1451 pictograms, basic written information has shown valuable for educating patients about CPT
1452 [80]. Nevertheless, such patient leaflets are still not available in all countries, reemphasising
1453 the importance of effective provider-patient communication during direct patient contact.

1454 **Facilitators to preventive therapies**

1455 As barriers vary between and within high TB/HIV burden countries, there is not one
1456 strategy for improving the implementation of either or both preventive therapies that fits all
1457 settings. We, therefore, encourage redesigning an implementation strategy that addresses
1458 barriers identified in a specific context. The awareness of implementation challenges and
1459 political williness to tackle these issues are critical first steps for continuous improvement.
1460 Routinely collected indicators, district-level evaluations, dialogues with implementers or local

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1461 research findings may indicate difficulties with the implementation of one or both preventive
1462 therapies on a national level or in a specific setting. Our review identified only a few
1463 intervention-specific barriers and highlighted that cross-cutting barriers often affect the
1464 implementation of both preventive therapies and potentially other interventions in high
1465 TB/HIV burden countries. On the one hand, the resulting awareness that strategies are
1466 needed to target systematic weaknesses, as well as an intervention on its own, can be
1467 daunting. On the other hand, integrating the concept of health systems strengthening into an
1468 implementation strategy provides new opportunities for policymakers and health systems.
1469 These opportunities include improvements in health system sustainability, effectiveness and
1470 the availability of international support for health systems strengthening.

1471 First, health systems strengthening may still appear unrealistic in low-income
1472 countries where primary care facilities struggle to provide basic health services and essential
1473 medicines. Additionally, funding mechanisms have partially encouraged vertical health
1474 system organisation and made it more difficult for health systems strengthening to be
1475 achieved in low- and middle-income countries. However, the decision for ‘organisational
1476 transformation’ is not based on the capacity of an individual primary care facility but rather,
1477 the potential behind removing cross-programmatic duplications and leveraging the existing
1478 resources. Transforming a health system structurally from fully vertical (e.g. disease-specific)
1479 programmes into a horizontally organised health system should be a gradual process.
1480 Similarly, others have argued that a phased, targeted and incremental transition from a
1481 vertical HIV response to a more efficient and sustainable health system response should be
1482 the way forward [71]. Adapting the implementation strategy of a high-impact multi-
1483 programmatic intervention, such as IPT, provides an opportunity to contribute to a more
1484 sustainable health system transformation.

1485 Second, we understand that health systems strengthening is ambitious to achieve
1486 holistically, is difficult to measure and can be expected to take a long time. However,
1487 targeted strengthening of a selected health system component, such as up-skilling

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1488 leadership and governance, reinforcing health providers' capacity and knowledge,
1489 strengthening supply chains or health information systems comprise examples frequently
1490 identified in this review with the potential to yield benefits across both preventive therapies
1491 and a wide range of other health interventions. In addition, strengthening an individual health
1492 system component can help relax capacity constraints, result in cost-sharing, increase
1493 efficiency and cost-effectiveness of individual interventions. Cost-effectiveness analysis can
1494 assist in establishing the optimal balance between systems strengthening- and intervention-
1495 specific approaches to be included in an implementation strategy [82].

1496 Third, vertical programmes of the past were popular for their 'quantifying of lives
1497 saved' approach that promised and short term objectives that promised quick and
1498 measurable results [83]. However, disease-specific programmes and initiatives were
1499 criticised for their costly parallel structures, less sustained impact, and for negatively
1500 affecting non-HIV care [72, 83]. In high TB/HIV burden countries that depend on external
1501 funds to finance their HIV response, vertical programming was associated with donor-driven
1502 policy evolution and investment decisions that were not always aligned with national
1503 priorities [56]. 'Pushing' global recommendations without considering context-specific
1504 constraints undermines the competence of local policymakers and can create tension
1505 between donors and recipient countries' governments and weaken local policy ownership.
1506 For example, instead of prioritising prevention activities, donors' investment focus was
1507 considered primarily strong on medicines, without adequate consideration of health system
1508 capacity (e.g. human resources) on which the delivery of these medicines is dependent [14,
1509 56, 71].

1510 However, many of these issues have been recognised internationally, and the global
1511 health systems strengthening movement has finally gained momentum [84, 85]. Major HIV
1512 funding bodies (i.e. USAID, Global Fund) have begun promoting the 'de-verticalisation' of
1513 fragmented programming [84, 86]. Both, the U.S. Agency for International Development
1514 (USAID) and the Global Fund to fight AIDS, TB and Malaria (Global Fund) have incorporated

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1515 systems strengthening objectives into their strategy [84, 86] and updated their policies to
1516 include funding agreements for health systems strengthening that allow direct disbursement
1517 of funds to the recipient country's state budget [83, 87]. Dialogues between donors and local
1518 system stakeholders (e.g. USAID's Government to Government (G2G) assistance, Global
1519 Fund's country coordinating mechanism (CCM)) support alignment of policies with country
1520 priorities [83, 87], encouraging mutually beneficial decisions and better relationships
1521 between donors and recipient countries. Additionally, the new implementation science
1522 culture encourages consideration of national, regional and local lessons learnt [46, 63, 88].
1523 To sum up, the foundation for change has been laid. It is now up to high burden countries'
1524 governments to make best use of the support and domestic resources available for health to
1525 collaboratively select, plan and coordinate an implementation strategy that addresses
1526 context-specific barriers and maximises the likelihood of long-term sustainability of both
1527 interventions.

1528 **Strengths and limitations**

1529 The main strength of this review is the in-depth understanding that this review
1530 provides about the challenges associated with the implementation of CPT and IPT in
1531 countries with a high burden of TB and HIV. To explore the existing body of evidence
1532 holistically, (1) we applied a comprehensive search strategy, (2) included all stakeholders
1533 involved in the implementation process as study population, (3) integrated research with
1534 different study designs, and (4) presented the identified barriers within each of the building
1535 blocks of the health system. First, we systematically searched three databases, using a
1536 combination of MeSH and free-text terms. In addition, we manually screened reference lists
1537 of systematic reviews for original research eligible for this review. Second, our review
1538 included studies that reported the perspectives and experiences of any stakeholder involved
1539 in the implementation process, encompassing patients' and health providers' views that are
1540 otherwise often disregarded in the implementation process. Third, the integration of studies

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1541 with different study designs further enhanced the richness of our findings. Mixed methods
1542 systematic reviews have gained increasing scientific attention in the areas of public health
1543 and complex interventions, where typically decision makers require consideration of different
1544 types of data and information (e.g. accessibility, feasibility, patient values and preferences)
1545 [18]. Fourth, for the qualitative evidence synthesis of barrier information, we applied a highly
1546 transparent deductive approach using an a priori defined coding framework of seven health
1547 system components (a modification of the WHO's Framework for action) [27]. Qualitative
1548 evidence synthesis is relatively new compared to quantitatively oriented systematic reviews
1549 and the application of metasummary to compare interventions with respect to similarities and
1550 differences of barriers employed in our review is innovative.

1551 Potential limitations of our review include (1) restrictions in our search strategy, (2)
1552 methodological limitations of the included studies, (3) heterogeneity of study characteristics,
1553 and (4) potential biases introduced through the non-availability of studies or the non-
1554 dissemination of study findings. First, although our search strategy was systematic and
1555 rigorous, it only included peer-reviewed publications reported in the English language. This
1556 is unlikely to be a major limitation considering that twenty-three high burden countries were
1557 represented in this review. However, this may explain why most studies included in this
1558 review, were carried out in South Africa, Uganda and Tanzania. Only including peer-
1559 reviewed published studies may have led to the exclusion of potentially useful grey reports
1560 (e.g. HIV progress reports). Second, we did not exclude any study from our analysis
1561 regardless of the methodological limitations. However, we systematically assessed each
1562 study's strengths and limitations and carefully considered issues of bias, validity, and
1563 trustworthiness. Third, we identified a heterogeneous representation of the study populations
1564 represented in our review. Most of the included studies presented the perspectives of
1565 patients and health providers. Consequently, the views of caregivers, community members
1566 and other stakeholders involved in the implementation process were less frequently
1567 represented, limiting the generalisability of our findings. However, generalising findings was

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1568 outside the scope of this review. Therefore, the primary concern about this observation is the
1569 extent to which our findings holistically represent the phenomena of interest. Fourth, non-
1570 availability or non-dissemination of studies may have limited the completeness of our study
1571 findings [30]. Studies on the subject of this review may be less likely to be available in
1572 countries with limited political interest to implement the concerned preventive therapies. In
1573 high TB/HIV burden countries with little research capacity, available study findings may be
1574 more likely to be published in local journals that are not indexed in major databases.

1575 **Conclusion**

1576 There is little benefit to any highly efficacious therapy as long as we are unable to
1577 effectively implement it under ‘real-world’ conditions.

1578 For policymakers who encounter challenges with the implementation of either or both
1579 preventive therapies, this review offers a list of strategies for improving the implementation of
1580 both preventive therapies. Based on evidence from high TB/HIV burden countries, this list
1581 includes specific direction for improving the delivery of IPT (or any newer therapy regimen)
1582 for the prevention of TB. For researchers with limited working experience in high TB/HIV
1583 burden countries, this review can provide useful insights regarding to which barriers may
1584 arise at different levels of the health system. The barrier description provided in this review
1585 highlights the complexity of social interactions involved in the delivery of preventive
1586 therapies.

1587 Overall, our review showed that until today, many high TB/HIV burden countries’
1588 health systems are not prepared to ensure appropriate public healthcare for the ever
1589 increasing number of patients in need of HIV services. From this standpoint, health system
1590 strengthening is imperative for the sustainable delivery of both preventive therapies for
1591 PLHIV, but particularly for IPT. Based on our findings, we suggest consideration of two
1592 important aspects to implementation. First, we recommend early engagement of

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1593 stakeholders when shaping an implementation strategy. Involving patients and health
1594 providers in the process of policy development and planning may increase awareness and
1595 understanding about the intervention and help to ensure its acceptability. Additional
1596 stakeholders (e.g. church leaders, traditional healers) may be involved, if appropriate.
1597 Second, during the adaptation of an implementation strategy, we urge that attention is paid
1598 to the fact that many of the countries with the highest burden of TB and HIV to date are also
1599 among the most resource-constrained countries. Thus, novel strategies for the
1600 implementation of preventive therapies may appear encouraging at first, but in high TB/HIV
1601 burden settings, they are often far from feasible or sustainable on a big scale. Instead, we
1602 encourage innovative approaches that consider the resources available at the health facility
1603 level, and investing into strengthening the existing capacities.

1604 Future research is warranted to test and evaluate alternative service delivery
1605 approaches that reduce the financial and organisational burden that patients face during the
1606 course of preventive therapy. Replacing INH with one of the shorter treatment regimen
1607 recommended by WHO for the prevention of TB [13] and the community-based delivery of
1608 selected activities related to the provision of PT's may comprise two options with the
1609 additional benefit of reducing the patient load at the overburdened health facilities.

1610

1611 **Funding**

1612 This study was funded by the Portuguese Foundation for Science and Technology
1613 (Fundação para a Ciência e a Tecnologia - FCT, www.FCT.pt), through funds to the Global
1614 Health and Tropical Medicine Research Center (Grant number: GHTM -
1615 UID/Multi/04413/2013). The study was supported by funds from the German Federal Ministry
1616 of Education and Research (Bundesministerium für Bildung und Forschung – BMBF,
1617 <https://www.bmbf.de/>), through funds to the Hans-Böckler Stiftung (HBS). LVL was funded

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1618 by the FCT grant. PM received a Research Scholarship from the HBS (PhD Scholarship ID:
1619 385759). The funders had no role in study design, data collection and analysis, decision to
1620 publish, or preparation of the manuscript.

1621 **Acknowledgement**

1622 We would like to express our gratitude to Jonathan O' Mahony for proofreading the
1623 manuscript. In addition, we would like to thank Carlos Rodrigues, IT specialist at the Institute
1624 of Hygiene & Tropical Medicine in Lisbon for his support with formatting the graphics
1625 included in this manuscript.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1626 **References**

- 1627 1. UNAIDS. Global HIV & AIDS statistics - 2020 fact sheet. 2020. Available from:
1628 <https://www.unaids.org/en/resources/fact-sheet>.
- 1629 2. World Health Organization. Global Tuberculosis Report 2020. 2020. Available from:
1630 <https://www.who.int/publications/i/item/9789240013131>.
- 1631 3. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent
1632 tuberculosis: a systematic review and meta-analysis. The European respiratory
1633 journal. 2019;54(3). Epub 2019/06/22. doi: 10.1183/13993003.00655-2019. PubMed
1634 PMID: 31221810.
- 1635 4. World Health Organization. WHO consolidated guidelines on tuberculosis:
1636 tuberculosis preventive treatment: Module 1. Prevention: Tuberculosis preventive
1637 treatment 2020. Available from: [https://www.who.int/publications/i/item/who-](https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment)
1638 [consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-](https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment)
1639 [preventive-treatment](https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment).
- 1640 5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs
1641 for treating and preventing HIV infection. chapter 5: Clinical guidelines: Managing
1642 common coinfections and comorbidities.: World Health Organization; 2016. Available
1643 from: <https://www.who.int/hiv/pub/arv/arv-2016/en/>.
- 1644 6. Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, et al. Co-
1645 trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic
1646 review and meta-analysis. The Lancet HIV. 2015;2(4):e137-e50.
- 1647 7. Geremew D, Endalamaw A, Negash M, Eshetie S, Tessema B. The protective effect
1648 of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients
1649 receiving ART in Ethiopian settings: a meta-analysis. BMC infectious diseases.
1650 2019;19(1):405. doi: 10.1186/s12879-019-4031-2.
- 1651 8. Eholié SP, Ello FN, Coffie PA, Héma A, Minta DK, Sawadogo A. Effect of
1652 cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West
1653 Africa: the MALHIV Study. Tropical Medicine and International Health.
1654 2017;22(9):1186-95. Epub 2017/06/28. doi: 10.1111/tmi.12919. PubMed PMID:
1655 28653454.
- 1656 9. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of
1657 isoniazid preventive therapy on risk of death in west African, HIV-infected adults with
1658 high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. The
1659 Lancet Global Health. 2017;5(11):e1080-e9.
- 1660 10. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection
1661 in HIV infected persons. Cochrane database of systematic reviews. 2010;(1). doi:
1662 10.1002/14651858.CD000171.pub3.
- 1663 11. World Health Organization. Provisional WHO/UNAIDS Secretariat recommendations
1664 on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in
1665 Africa. African Health Sciences. 2000;1(1):30-1.
- 1666 12. WHO/ UNAIDS. Policy statement on preventive therapy against tuberculosis in
1667 people living with HIV 1998. Available from:
1668 [https://apps.who.int/iris/bitstream/handle/10665/64509/WHO_TB_98.255.pdf?sequen](https://apps.who.int/iris/bitstream/handle/10665/64509/WHO_TB_98.255.pdf?sequence=1)
1669 [ce=1](https://apps.who.int/iris/bitstream/handle/10665/64509/WHO_TB_98.255.pdf?sequence=1).
- 1670 13. World Health Organization. Tuberculosis. Key facts 2020. 14 October 2020:[Available
1671 from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1672 14. Mugomeri E, Olivier D, Van Den Heever WM. Health system challenges affecting the
1673 implementation of isoniazid preventive therapy in people living with HIV in Lesotho.
1674 HIV and AIDS Review. 2018;17(4):299-307. doi: 10.5114/hivar.2018.80263.
- 1675 15. Kamuhabwa AAR, Manyanga V. Challenges facing effective implementation of
1676 cotrimoxazole prophylaxis in children born to HIV-infected mothers in the public
1677 health facilities. Drug, healthcare and patient safety. 2015;7:147-56. doi:
1678 10.2147/dhps.s89115. PubMed PMID: WOS:000215804900017.
- 1679 16. Thabane L, Thomas T, Ye C, Paul J. Posing the research question: not so simple.
1680 Canadian journal of anaesthesia. 2009;56(1):71.
- 1681 17. Butler A, Hall H, Copnell B. A guide to writing a qualitative systematic review protocol
1682 to enhance evidence-based practice in nursing and health care. Worldviews on
1683 Evidence-Based Nursing. 2016;13(3):241-9.
- 1684 18. Joanna Briggs Institute. JBI Reviewer's Manual. Chapter 8: Mixed methods
1685 systematic reviews. Section 8.5.1 Mixed methods systematic review using a
1686 convergent integrated approach to synthesis and integration. 2017 [cited 1]. Available
1687 from:
1688 [https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+](https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration)
1689 [using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration](https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration).
- 1690 19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
1691 reviews and meta-analyses: the PRISMA statement. Annals of internal medicine.
1692 2009;151(4):264-9.
- 1693 20. Cumpston M, Chandler J. Chapter IV: updating a review 2019. Available from:
1694 <https://training.cochrane.org/handbook/current/chapter-iv>.
- 1695 21. Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed
1696 methods appraisal tool (MMAT), version 2018. User guide. 2018. Available from:
1697 [http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)
1698 [2018_criteria-manual_2018-08-01_ENG.pdf](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf).
- 1699 22. Noyes J, Booth A, Flemming K, Garside R, Harden A, Lewin S, et al. Cochrane
1700 Qualitative and Implementation Methods Group guidance series - paper 3: methods
1701 for assessing methodological limitations, data extraction and synthesis, and
1702 confidence in synthesized qualitative findings. Journal of clinical epidemiology.
1703 2018;97:49-58.
- 1704 23. Hannes K. Chapter 4: Critical appraisal of qualitative research: Cochrane
1705 Collaboration Qualitative Methods Group, 2011; 2011. Available from:
1706 <http://cqrng.cochrane.org/supplemental-handbook-guidance>.
- 1707 24. Sandelowski M, Barroso J, Voils CI. Using qualitative metasummary to synthesize
1708 qualitative and quantitative descriptive findings. Research in nursing & health.
1709 2007;30(1):99-111.
- 1710 25. Petticrew M, Rehfuess E, Noyes J, Higgins JP, Mayhew A, Pantoja T, et al.
1711 Synthesizing evidence on complex interventions: how meta-analytical, qualitative,
1712 and mixed-method approaches can contribute. 2013;66(11):1230-43.
- 1713 26. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al.
1714 Implementation of isoniazid preventive therapy for people living with HIV worldwide:
1715 barriers and solutions. AIDS. 2010;24:S57-S65.
- 1716 27. World Health Organization. Monitoring the building blocks of health systems: a
1717 handbook of indicators and their measurement strategies: World Health
1718 Organization; 2010. Available from:
1719 https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1720 28. Asonganyi E, Vaghasia M, Rodrigues C, Phadtare A, Ford A, Pietrobon R, et al.
1721 Factors affecting compliance with clinical practice guidelines for pap smear screening
1722 among healthcare providers in africa: systematic review and meta-summary of 2045
1723 individuals. PLoS ONE. 2013;8(9):e72712. Epub 2013/09/27. doi:
1724 10.1371/journal.pone.0072712. PubMed PMID: 24069156; PubMed Central PMCID:
1725 PMCPMC3771969.
- 1726 29. Petticrew M, Egan M, Thomson H, Hamilton V, Kunkler R, Roberts H. Publication
1727 bias in qualitative research: what becomes of qualitative research presented at
1728 conferences? Journal of Epidemiology and Community Health. 2008;62(6):552-4.
1729 doi: 10.1136/jech.2006.059394.
- 1730 30. Booth A, Lewin S, Glenton C, Munthe-Kaas H, Toews I, Noyes J, et al. Applying
1731 GRADE-CERQual to qualitative evidence synthesis findings—paper 7: understanding
1732 the potential impacts of dissemination bias. Implementation Science. 2018;13(1):12.
1733 doi: 10.1186/s13012-017-0694-5.
- 1734 31. Okwera A, Mafigiri DK, Guwatudde D, Whalen C, Joloba M. Level of understanding
1735 of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis
1736 suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative
1737 analysis. Afr Health Sci. 2015;15(1):49-57. Epub 2015/04/04. doi:
1738 10.4314/ahs.v15i1.7. PubMed PMID: 25834530; PubMed Central PMCID:
1739 PMCPmc4370121.
- 1740 32. Chang LW, Nakigozi G, Billioux VG, Gray RH, Serwadda D, Quinn TC, et al.
1741 Effectiveness of Peer Support on Care Engagement and Preventive Care
1742 Intervention Utilization Among Pre-antiretroviral Therapy, HIV-Infected Adults in
1743 Rakai, Uganda: A Randomized Trial. AIDS and Behavior. 2015;19(10):1742-51. doi:
1744 10.1007/s10461-015-1159-y.
- 1745 33. Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, et al. The
1746 Lablite project: A cross-sectional mapping survey of decentralized HIV service
1747 provision in Malawi, Uganda and Zimbabwe. BMC health services research. 2014;14.
1748 doi: 10.1186/1472-6963-14-352. PubMed PMID: WOS:000340917700001.
- 1749 34. Sibanda EL, Bernays S, Weller IV, Hakim JG, Cowan FM. Manuscript title:
1750 Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a
1751 qualitative study from Harare, Zimbabwe. BMC public health. 2015;15:784. Epub
1752 2015/08/16. doi: 10.1186/s12889-015-2136-0. PubMed PMID: 26276143; PubMed
1753 Central PMCID: PMCPmc4536866.
- 1754 35. Mwambete KD, Kamuhabwa AA. Resistance of commensal intestinal Escherichia coli
1755 and other enterics to co-trimoxazole and commonly used antibiotics in HIV/AIDS
1756 patients. Clinical Microbiology: Open Access. 2013.
- 1757 36. Kamuhabwa AA, Gordian R, Mutagonda RF. Implementation of co-trimoxazole
1758 preventive therapy policy for malaria in HIV-infected pregnant women in the public
1759 health facilities in Tanzania. Drug, healthcare and patient safety. 2016;8:91-100.
1760 Epub 2016/12/23. doi: 10.2147/dhps.s119073. PubMed PMID: 28008284; PubMed
1761 Central PMCID: PMCPmc5167525.
- 1762 37. Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M.
1763 Missed opportunities for accessing HIV care among Tshwane tuberculosis patients
1764 under different models of care. Int J Tuberc Lung Dis. 2012;16(8):1052-8. doi:
1765 10.5588/ijtld.11.0753. PubMed PMID: WOS:000306678800012.
- 1766 38. Okot-Chono R, Mugisha F, Adatu F, Madraa E, Dlodlo R, Fujiwara P. Health system
1767 barriers affecting the implementation of collaborative TB-HIV services in Uganda. Int
1768 J Tuberc Lung Dis. 2009;13(8):955-61.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1769 39. Naikoba S, Senjovu KD, Mugabe P, McCarthy CF, Riley PL, Kadengye DT, et al.
1770 Improved HIV and TB Knowledge and Competence among Mid-level Providers in a
1771 Cluster-Randomized Trial of One-on-One Mentorship for Task Shifting. *Journal of*
1772 *Acquired Immune Deficiency Syndromes*. 2017;75(5):e120-e7. doi:
1773 10.1097/QAI.0000000000001378.
- 1774 40. Luyirika E, Towle MS, Achan J, Muhangi J, Senyimba C, Lule F, et al. Scaling Up
1775 Paediatric HIV Care with an Integrated, Family-Centred Approach: An Observational
1776 Case Study from Uganda. *PLoS ONE*. 2013;8(8). doi:
1777 10.1371/journal.pone.0069548. PubMed PMID: WOS:000324401500013.
- 1778 41. Ansa GA, Walley JD, Siddiqi K, Wei X. Delivering TB/HIV services in Ghana: a
1779 comparative study of service delivery models. *Transactions of the Royal Society of*
1780 *Tropical Medicine and Hygiene*. 2014;108(9):560-7. doi: 10.1093/trstmh/tru110.
1781 PubMed PMID: WOS:000343059500009.
- 1782 42. Horwood C, Haskins L, Vermaak K, Phakathi S, Subbaye R, Doherty T. Prevention of
1783 mother to child transmission of HIV (PMTCT) programme in KwaZulu-Natal, South
1784 Africa: an evaluation of PMTCT implementation and integration into routine maternal,
1785 child and women's health services. *Tropical Medicine and International Health*.
1786 2010;15(9):992-9. Epub 2010/06/22. doi: 10.1111/j.1365-3156.2010.02576.x.
1787 PubMed PMID: 20561313.
- 1788 43. Adepoju AV, Ogbudebe CL, Adejumo OA, Okolie J, Inegbeboh JO. Implementation
1789 of Isoniazid Preventive Therapy among People Living with HIV in Northwestern
1790 Nigeria: Completion Rate and Predictive Factors. *J Glob Infect Dis*. 2020;12(2):105-
1791 11. Epub 2020/08/11. doi: 10.4103/jgid.jgid_138_18. PubMed PMID: 32773999;
1792 PubMed Central PMCID: PMC7384686.
- 1793 44. Aisu T, Raviglione MC, Eriki P, Narain J, Barugahare L, Tembo G, et al. Preventive
1794 chemotherapy for HIV-associated tuberculosis in Uganda: an operational
1795 assessment at a voluntary counselling and testing centre. *AIDS*. 1995;9(3):267-73.
- 1796 45. Catalani C, Green E, Owiti P, Keny A, Diero L, Yeung A, et al. A Clinical Decision
1797 Support System for Integrating Tuberculosis and HIV Care in Kenya: A Human-
1798 Centered Design Approach. *PLoS ONE*. 2014;9(8). doi:
1799 10.1371/journal.pone.0103205. PubMed PMID: WOS:000341127500009.
- 1800 46. Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, et al. The
1801 implementation of isoniazid preventive therapy in HIV clinics: the experience from the
1802 TB/HIV in Rio (THRio) study. *AIDS*. 2010;24(Suppl 5):S49.
- 1803 47. Faust L, Ruhwald M, Schumacher S, Pai M. How are high burden countries
1804 implementing policies and tools for latent tuberculosis infection? A survey of current
1805 practices and barriers. *Health Sci Rep*. 2020;3(2):e158. Epub 2020/05/07. doi:
1806 10.1002/hsr2.158. PubMed PMID: 32373716; PubMed Central PMCID:
1807 PMC7196590.
- 1808 48. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al.
1809 Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in
1810 Botswana. *PLoS ONE*. 2011;6(4):e18435.
- 1811 49. Huerga H, Mueller Y, Ferlazzo G, Mpala Q, Bevilacqua P, Vasquez B, et al.
1812 Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test
1813 Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected
1814 Patients in Resource-Constrained Settings. *JAIDS*. 2016;71(4):e89-95. Epub
1815 2016/02/26. doi: 10.1097/qai.0000000000000895. PubMed PMID: 26910386.
- 1816 50. Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Sheno SV. "It's about my life":
1817 facilitators of and barriers to isoniazid preventive therapy completion among people

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1818 living with HIV in rural South Africa. *AIDS Care*. 2017;29(7):936-42. doi:
1819 10.1080/09540121.2017.1283390. PubMed PMID: WOS:000402669100019.
- 1820 51. Jarrett BA, Woznica DM, Tilchin C, Mpungose N, Motlhaoleng K, Golub JE, et al.
1821 Promoting Tuberculosis Preventive Therapy for People Living with HIV in South
1822 Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced
1823 Patient-Provider Dynamics. *AIDS and Behavior*. 2019;24(4):1106-17. doi:
1824 10.1007/s10461-019-02675-6. PubMed PMID: WOS:000520707300012.
- 1825 52. Khan FA, Verkuijl S, Parrish A, Chikwava F, Ntummy R, El-Sadr W, et al. Performance
1826 of symptom-based tuberculosis screening among people living with HIV: not as great
1827 as hoped. *AIDS*. 2014;28(10):1463-72. doi: 10.1097/qad.0000000000000278.
1828 PubMed PMID: WOS:000337705400009.
- 1829 53. Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, et al. Provider
1830 barriers to the uptake of isoniazid preventive therapy among people living with HIV in
1831 Ethiopia. *Int J Tuberc Lung Dis*. 2019;23(3):371-7. Epub 2019/03/16. doi:
1832 10.5588/ijtld.18.0378. PubMed PMID: 30871669; PubMed Central PMCID:
1833 PMC6822021.
- 1834 54. Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, et
1835 al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: A
1836 qualitative study. *AIDS*. 2010;24(SUPPL. 5):S45-S8. doi:
1837 10.1097/01.aids.0000391021.18284.12.
- 1838 55. Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, et al.
1839 Predictors of isoniazid preventive therapy completion among adults newly diagnosed
1840 with HIV in rural Malawi. *Int J Tuberc Lung Dis*. 2018;22(4):371-7. Epub 2018/03/23.
1841 doi: 10.5588/ijtld.16.0836.
- 1842 56. McRobie E, Wringe A, Nakiyingi-Miiró J, Kiweewa F, Lutalo T, Nakigozi G, et al. HIV
1843 policy implementation in two health and demographic surveillance sites in Uganda:
1844 Findings from a national policy review, health facility surveys and key informant
1845 interviews. *Implementation Science*. 2017;12(1). doi: 10.1186/s13012-017-0574-z.
- 1846 57. Meribe SC, Adamu Y, Adebayo-Abikoye E, Lawal I, Amazue-Ezeuko I, Okeji N, et al.
1847 Sustaining tuberculosis preventive therapy scale-up through direct supportive
1848 supervision. *Public Health Action*. 2020;10(2):60-3. Epub 2020/07/09. doi:
1849 10.5588/pha.20.0003. PubMed PMID: 32639481; PubMed Central PMCID:
1850 PMC7316438.
- 1851 58. Mindachew M, Deribew A, Tessema F, Biadgilign S. Predictors of adherence to
1852 isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
1853 *BMC public health*. 2011;11(1):916.
- 1854 59. Mugomeri E, Olivier D, van den Heever WMJ. Tracking the rate of initiation and
1855 retention on isoniazid preventive therapy in a high human immunodeficiency virus
1856 and tuberculosis burden setting of Lesotho. *Southern African Journal of Infectious
1857 Diseases*. 2019;34(1). doi: 10.4102/sajid.v34i1.10. PubMed PMID:
1858 WOS:000519626300001.
- 1859 60. Munseri P, Talbot E, Mtei L, Fordham von Reyn C. Completion of isoniazid
1860 preventive therapy among HIV-infected patients in Tanzania. *Int J Tuberc Lung Dis*.
1861 2008;12(9):1037-41.
- 1862 61. Ngamvithayapong J, Uthavivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P.
1863 Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang
1864 Rai, Thailand. *AIDS*. 1997;11(1):107-12.
- 1865 62. Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, et al. To
1866 start or to complete? - Challenges in implementing tuberculosis preventive therapy

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1867 among people living with HIV: a mixed-methods study from Karnataka, India. *Glob*
1868 *Health Action.* 2020;13(1):1704540. Epub 2020/01/16. doi:
1869 10.1080/16549716.2019.1704540. PubMed PMID: 31937200; PubMed Central
1870 PMCID: PMC7006687.
- 1871 63. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM.
1872 Adherence to TB preventive therapy for HIV-positive patients in rural South Africa:
1873 implications for antiretroviral delivery in resource-poor settings? *Int J Tuberc Lung*
1874 *Dis.* 2005;9(3):263-9. Epub 2005/03/25. PubMed PMID: 15786888.
- 1875 64. Selehelo K, Makhado L, Madiba KA. Provision of Isoniazid Preventive Therapy: The
1876 Experiences of People Living with HIV. *African Journal of Nursing and Midwifery.*
1877 2019;21(2). doi: 10.25159/2520-5293/6221. PubMed PMID:
1878 WOS:000532581600019.
- 1879 65. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, et al.
1880 Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in
1881 South Africa. *BMC infectious diseases.* 2006;6(1):97.
- 1882 66. Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, et al.
1883 Predictors of isoniazid preventive therapy completion among HIV-infected patients
1884 receiving differentiated and non-differentiated HIV care in rural Uganda. *AIDS Care.*
1885 2019;32(1):119-27. doi: 10.1080/09540121.2019.1619661. PubMed PMID:
1886 WOS:000498969900018.
- 1887 67. Van Ginderdeuren E, Bassett J, Hanrahan C, Mutunga L, Van Rie A. Health system
1888 barriers to implementation of TB preventive strategies in South African primary care
1889 facilities. *PLoS ONE.* 2019;14(2):e0212035. Epub 2019/02/15. doi:
1890 10.1371/journal.pone.0212035. PubMed PMID: 30763378; PubMed Central PMCID:
1891 PMC6375590.
- 1892 68. Wambiya EOA, Atela M, Eboreime E, Ibisomi L. Factors affecting the acceptability of
1893 isoniazid preventive therapy among healthcare providers in selected HIV clinics in
1894 Nairobi County, Kenya: a qualitative study. *BMJ Open.* 2018;8(12):e024286. Epub
1895 2018/12/24. doi: 10.1136/bmjopen-2018-024286. PubMed PMID: 30573488; PubMed
1896 Central PMCID: PMC6303693.
- 1897 69. The World Bank. World Bank country and lending groups 2021. Available from:
1898 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
1899 [country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).
- 1900 70. Kates J, Wexler A, Lief E. Donor government funding for HIV in low-and middle-
1901 income countries in 2019 2020. Available from: [https://files.kff.org/attachment/Donor-](https://files.kff.org/attachment/Donor-Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf)
1902 [Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf](https://files.kff.org/attachment/Donor-Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf).
- 1903 71. Assefa Y, Gilks CF. Ending the epidemic of HIV/AIDS by 2030: Will there be an
1904 endgame to HIV, or an endemic HIV requiring an integrated health systems response
1905 in many countries? *International Journal of Infectious Diseases.* 2020;100:273-7. doi:
1906 <https://doi.org/10.1016/j.ijid.2020.09.011>.
- 1907 72. Luboga SA, Stover B, Lim TW, Makumbi F, Kiwanuka N, Lubega F, et al. Did
1908 PEPFAR investments result in health system strengthening? A retrospective
1909 longitudinal study measuring non-HIV health service utilization at the district level.
1910 *Health Policy Plan.* 2016;31(7):897-909. Epub 2016/03/27. doi:
1911 10.1093/heapol/czw009. PubMed PMID: 27017824.
- 1912 73. Mikkelsen E, Hontelez JA, Jansen MP, Bärnighausen T, Hauck K, Johansson KA, et
1913 al. Evidence for scaling up HIV treatment in sub-Saharan Africa: a call for
1914 incorporating health system constraints. *PLoS medicine.* 2017;14(2):e1002240.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1915 74. Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole
1916 prophylaxis and isoniazid preventive therapy for people living with HIV. Bulletin of the
1917 World Health Organization. 2010;88:253-9.
- 1918 75. Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the
1919 prevalence of drug resistance? Causes and consequences. Philosophical
1920 Transactions of the Royal Society B: Biological Sciences. 2015;370(1670):20140306.
- 1921 76. Kafu C, Wachira J, Braitstein P, Wilson I, Koech B, Kamene R, et al. Provider
1922 perspectives on the role of the patient as an active participant in HIV care. Global
1923 public health. 2020:1-11. doi: 10.1080/17441692.2020.1830296.
- 1924 77. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial
1925 Susceptibility Testing, 31st Edition: CLSI; 2020 [cited 35]. 1-332]. Available from:
1926 <https://clsi.org/standards/products/microbiology/documents/m100-preorder/>.
- 1927 78. Ersoy SC, Heithoff DM, Barnes Lt, Tripp GK, House JK, Marth JD, et al. Correcting a
1928 Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing.
1929 EBioMedicine. 2017;20:173-81. Epub 2017/05/29. doi: 10.1016/j.ebiom.2017.05.026.
1930 PubMed PMID: 28579300.
- 1931 79. Zachariah R, Massaquoi M. Cotrimoxazole prophylaxis for HIV-positive TB patients in
1932 developing countries. Tropical doctor. 2006;36(2):79-82.
- 1933 80. Mansoor L, Dowse R. Written medicines information for South African HIV/AIDS
1934 patients: does it enhance understanding of co-trimoxazole therapy? Health Education
1935 Research. 2006;22(1):37-48. doi: 10.1093/her/cyl039.
- 1936 81. Kenny T, Wilson R, Purves I, Clark Sr J, Newton L, Newton D, et al. A PIL for every
1937 ill? Patient information leaflets (PILs): a review of past, present and future use.
1938 Family Practice. 1998;15(5):471-9. doi: 10.1093/fampra/15.5.471.
- 1939 82. Hauck K, Morton A, Chalkidou K, Chi Y-L, Culyer A, Levin C, et al. How can we
1940 evaluate the cost-effectiveness of health system strengthening? A typology and
1941 illustrations. Social science & medicine. 2019;220:141-9. doi:
1942 10.1016/j.socscimed.2018.10.030.
- 1943 83. Steurs L, Orbie J, Delputte S, Verschaeve J. EU Donors and health system
1944 strengthening: the love-hate relationship with the Global Fund. Development Studies
1945 Research. 2018;5(sup1):S1-S13.
- 1946 84. USAID. USAID's vision for health systems strengthening 2030: Author Washington,
1947 DC; 2021. Available from:
1948 https://www.usaid.gov/sites/default/files/documents/USAID_OHS_VISION_Report_FINAL_single_5082.pdf.
1949
- 1950 85. World Health Organization. Healthy systems for universal health coverage: a joint
1951 vision for healthy lives 2018. Available from:
1952 https://www.uhc2030.org/fileadmin/uploads/uhc2030/Documents/About_UHC2030/mgt_arrangemts_docs/UHC2030_Official_documents/UHC2030_vision_paper_WEB_2.pdf.
1953
1954
- 1955 86. Global Fund. The Global Fund Strategy 2017–2022: investing to end epidemics:
1956 Reliefweb; 2017. Available from:
1957 https://www.theglobalfund.org/media/2531/core_globalfundstrategy2017-2022_strategy_en.pdf.
1958
- 1959 87. USAID. ADS Chapter 220: Use and Strengthening of Reliable Partner Government
1960 Systems for Implementation of Direct Assistance 2014. Available from: <https://2012-2017.usaid.gov/sites/default/files/documents/1868/220.pdf>.
1961

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1962 88. Rwabukwisi FC, Bawah AA, Gimbel S, Phillips JF, Mutale W, Drobac P. Health
1963 system strengthening: a qualitative evaluation of implementation experience and
1964 lessons learned across five African countries. BMC health services research.
1965 2017;17(3):77-89.

1966 **Supporting information**

1967 **Tables**

1968 Table 1. Main characteristics of the studies included in this review.

1969 Table 2. List of facilitators for the implementation of CPT and IPT.

1970 **Figures**

1971 Fig 1. PRISMA Flow Diagram.

1972 Fig 2. Regional representation of countries included in this review.

1973 Fig 3. Metasummary: Barriers to cotrimoxazole preventive therapy for people living with HIV.

1974 Fig 4. Metasummary: Barriers to isoniazid preventive therapy for people living with HIV.

1975 Fig 5. The preventive therapy cascade.

1976 **Additional files**

1977 S1 Additional file. PICo Framework (Modified PICO).

1978 S2 Additional file. Systematic review protocol.

1979 S3 Additional file. PRISMA checklist.

1980 S4 Additional file. Database searches and results.

1981 S5 Additional file. Mixed method quality appraisal tool (MMAT) and user guide.

1982 S6 Additional file. Detailed description of studies included in this review.

1983 S7 Additional file. Assessment of methodological strengths and limitations.

1984 S8 Additional file. Metasummary tables.

PRISMA 2009 Flow Diagram









